Fadlo Khuri MD

Department of Hematology and Medical Oncology
Professor

(404) 778-4250
fkhuri@emory.edu

Overview

Fadlo R. Khuri, MD, is the president of the American University of Beirut in Lebanon. Dr. Khuri maintains his appointment as Professor of the Department of Hematology and Medical Oncology at Emory University School of Medicine. He is the former Executive Associate Dean of Research and the former Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also served as Deputy Director for the Winship Cancer Institute of Emory University.

Dr. Khuri was also the Roberto C. Goizueta Distinguished Chair for Cancer Research. In his 13 years at Emory, he was instrumental in leading the development of some of the most important cancer-related programs in the state of Georgia and throughout the nation.

Academic Appointment

Professor of Hematology and Oncology, Pharmacology and Otolaryngology, Emory University School of Medicine

Education

Degrees

MD from Columbia University, College of Physicians and Surgeons
BS from Yale University
No Degree from The American University of Beirut
H.S. Diploma from The International College

Research

Focus

The overall goal of our research is to develop molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with aerodigestive cancers. We have developed prognostic models for stage I non-small cell lung cancer and have conducted phase I, II, and III studies on efficacy of novel agents, including oncolytic viruses, small molecule signal transduction, please update my other supportn inhibitors and natural compunds, in lung and head and neck cancers.

Publications

Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up.
Head Neck
04/28/2025 Authors: Kim P; Saba NF; McCook-Veal A; Liu Y; Klein AM; Beitler JJ; Chen A; Khuri FR; Shin DM
Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine.
CA Cancer J Clin Volume: 75 Page(s): 226 - 242
01/01/2025 Authors: Juweid ME; Al-Qasem SF; Khuri FR; Gallamini A; Lohmann P; Ziellenbach H-J; Mottaghy FM
Global disparities in cancer care: Bridging the gap in affordability and access to medications between high and low-income countries.
Cancer Volume: 131 Page(s): e35590
01/01/2025 Authors: Tfayli AH; El-Halabi LN; Khuri FR
Corrigendum to "Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E" [Neoplasia, volume 12, issue 10 (2010):848 -855].
Neoplasia Volume: 56 Page(s): 101031
10/01/2024 Authors: Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun S-Y
Climate Change and Cancer Care: A Policy Statement From ASCO.
JCO Oncol Pract Volume: 20 Page(s): 178 - 186
02/01/2024 Authors: Bernicker E; Averbuch SD; Edge S; Kamboj J; Khuri FR; Pierce JY; Schiller J; Sirohi B; Thomas A; Moushey A
Correction for Puckett et al., "Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-IB Kinase Cascade".
Mol Cell Biol Volume: 42 Page(s): e0028222
10/20/2022 Authors: Puckett MC; Goldman EH; Cockrell LM; Huang B; Kasinski AL; Du Y; Wang C-Y; Lin A; Ichijo H; Khuri F
A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Cancers (Basel) Volume: 14
05/26/2022 Authors: Bauman JE; Chen Z; Zhang C; Ohr JP; Ferris RL; McGorisk GM; Brandt S; Srivatsa S; Chen AY; Steuer CE
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Cell Volume: 185 Page(s): 1974 - 1985.e12
05/26/2022 Authors: Mo X; Niu Q; Ivanov AA; Tsang YH; Tang C; Shu C; Li Q; Qian K; Wahafu A; Doyle SP
The National Cancer Act of 1971: A seminal milestone in the fight against cancer.
Cancer Volume: 127 Page(s): 4532 - 4533
12/15/2021 Authors: Ramalingam SS; Khuri FR
Where it all began.
Cancer Volume: 127 Page(s): 4541 - 4545
12/15/2021 Authors: Khuri FR
Locally advanced lung cancer.
CA Cancer J Clin Volume: 71 Page(s): 461 - 465
11/01/2021 Authors: Tfayli AH; Sfeir PM; Youssef BY; Khuri FR
In Lebanon "It Never Rains But It Pours"-How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises.
FASEB Bioadv Volume: 3 Page(s): 676 - 682
09/01/2021 Authors: Khuri FR
The Beirut Port explosion: injury trends from a mass survey of emergency admissions.
Lancet Volume: 398 Page(s): 21 - 22
07/03/2021 Authors: Mansour HA; Bitar E; Fares Y; Makdessi AA; Maalouf A; Ghoul ME; Mansour MA; Chami A; Khalil M; Jalkh A
Passing the baton.
Cancer Volume: 127 Page(s): 1957 - 1958
06/15/2021 Authors: Khuri FR
From Cancer to COVID, Boston to Beirut.
Cancer Volume: 127 Page(s): 1172 - 1173
04/15/2021 Authors: Khuri FR
Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
Lung Cancer Volume: 154 Page(s): 228
04/01/2021 Authors: Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
Lung Cancer Volume: 154 Page(s): 227
04/01/2021 Authors: Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun S-Y; He Y; Zhou W
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
J Thorac Oncol Volume: 16 Page(s): 464 - 476
03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Oncotarget Volume: 12 Page(s): 251 - 252
02/02/2021 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175].
Cancer Lett Volume: 498 Page(s): 249 - 250
02/01/2021 Authors: Haque A; Rahman MA; Fuchs JR; Chen Z; Khuri FR; Shin DM; Amin ARMR
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
J Immunother Cancer Volume: 8
12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
Clin Cancer Res Volume: 26 Page(s): 5860 - 5868
11/15/2020 Authors: Shin DM; Nannapaneni S; Patel MR; Shi Q; Liu Y; Chen Z; Chen AY; El-Deiry MW; Beitler JJ; Steuer CE
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Cancer Med Volume: 9 Page(s): 8406 - 8411
11/01/2020 Authors: Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
Greetings from the front lines, when all the world is the front.
Cancer Volume: 126 Page(s): 4105 - 4106
09/15/2020 Authors: Khuri FR
Progress in breast cancer research amid the COVID-19 gloom.
Cancer Volume: 126 Suppl 16 Page(s): 3809 - 3810
08/15/2020 Authors: Khuri FR; O'Regan RM
Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
J Biol Chem Volume: 295 Page(s): 8870
06/26/2020 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y
Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IB degradation.
J Biol Chem Volume: 295 Page(s): 8869
06/26/2020 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
Oncologist Volume: 25 Page(s): e964 - e975
06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
Rare tumors in China: A step in the right direction.
Cancer Volume: 126 Suppl 9 Page(s): 2047
05/01/2020 Authors: Khuri FR
EXPRESSION OF CONCERN
ADVANCES IN NUTRITION Volume: 11 Page(s): 181 - 181
01/01/2020 Authors: Ghaedi E; Mohammadi M; Mohammadi H; Ramezani-Jolfaie N; Malekzadeh J; Hosseinzadeh M; Salehi-Abargouei A
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
The Immune Landscape of Cancer.
Immunity Volume: 51 Page(s): 411 - 412
08/20/2019 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA
A very personal war.
Cancer Volume: 125 Page(s): 2725 - 2727
08/15/2019 Authors: Khuri FR
Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res Volume: 25 Page(s): 4861
08/01/2019 Authors: Oh S-H; Kim W-Y; Kim J-H; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK
Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population.
J Thorac Dis Volume: 11 Page(s): 2383 - 2391
06/01/2019 Authors: Khoueiry P; Fakhri G; Akel R; El Assaad M; Mahfouz R; Khuri F; Chami H; Petersen J; Viet S; Davies G
Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.
Volume: 37
05/20/2019 Authors: Shin DM; Beitler JJ; El-Deiry M; Steuer CE; Chen AY; Baddour HM; Chen ZG; Roser S; Magliocca KR; Patel M
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G
The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center.
Cancer Volume: 125 Page(s): 1593 - 1596
05/15/2019 Authors: Khuri FR; Herbst RS
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Volume: 41 Page(s): 1490 - 1498
05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
J Thorac Oncol Volume: 14 Page(s): 876 - 889
05/01/2019 Authors: El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y.
Cancer Volume: 125 Page(s): 1200
04/01/2019
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
PLoS One Volume: 14 Page(s): e0206309
01/01/2019 Authors: Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun S-Y
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Cell Rep Volume: 25 Page(s): 1304 - 1317.e5
10/30/2018 Authors: Wang Y; Xu X; Maglic D; Dill MT; Mojumdar K; Ng PK-S; Jeong KJ; Tsang YH; Moreno D; Bhavana VH
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily.
Cell Syst Volume: 7 Page(s): 422 - 437.e7
10/24/2018 Authors: Korkut A; Zaidi S; Kanchi RS; Rao S; Gough NR; Schultz A; Li X; Lorenzi PL; Berger AC; Robertson G
On the humane side of medicine.
Cancer Volume: 124 Page(s): 3969 - 3970
10/15/2018 Authors: Khuri FR
Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Lung Cancer Volume: 123 Page(s): 36 - 43
09/01/2018 Authors: Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun S-Y; He Y; Zhou W
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
Cancer Cell Volume: 34 Page(s): 211 - 224.e6
08/13/2018 Authors: Kahles A; Lehmann K-V; Toussaint NC; Hser M; Stark SG; Sachsenberg T; Stegle O; Kohlbacher O; Sander C; Cancer Genome Atlas Research Network
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Cancer Cell Volume: 34 Page(s): 315 - 330.e7
08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell Volume: 174 Page(s): 1034 - 1035
08/09/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Cell Rep Volume: 23 Page(s): 3698
06/19/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R
The Immune Landscape of Cancer.
Immunity Volume: 48 Page(s): 812 - 830.e14
04/17/2018 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Cancer Cell Volume: 33 Page(s): 690 - 705.e9
04/09/2018 Authors: Berger AC; Korkut A; Kanchi RS; Hegde AM; Lenoir W; Liu W; Liu Y; Fan H; Shen H; Ravikumar V
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
Cancer Cell Volume: 33 Page(s): 721 - 735.e8
04/09/2018 Authors: Liu Y; Sethi NS; Hinoue T; Schneider BG; Cherniack AD; Sanchez-Vega F; Seoane JA; Farshidfar F; Bowlby R; Islam M
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
Cancer Cell Volume: 33 Page(s): 706 - 720.e9
04/09/2018 Authors: Wang Z; Yang B; Zhang M; Guo W; Wu Z; Wang Y; Jia L; Li S; Cancer Genome Atlas Research Network; Xie W
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
Cancer Cell Volume: 33 Page(s): 676 - 689.e3
04/09/2018 Authors: Taylor AM; Shih J; Ha G; Gao GF; Zhang X; Berger AC; Schumacher SE; Wang C; Hu H; Liu J
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Cell Volume: 173 Page(s): 291 - 304.e6
04/05/2018 Authors: Hoadley KA; Yau C; Hinoue T; Wolf DM; Lazar AJ; Drill E; Shen R; Taylor AM; Cherniack AD; Thorsson V
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Cell Volume: 173 Page(s): 305 - 320.e10
04/05/2018 Authors: Ding L; Bailey MH; Porta-Pardo E; Thorsson V; Colaprico A; Bertrand D; Gibbs DL; Weerasinghe A; Huang K-L; Tokheim C
Pathogenic Germline Variants in 10,389 Adult Cancers.
Cell Volume: 173 Page(s): 355 - 370.e14
04/05/2018 Authors: Huang K-L; Mashl RJ; Wu Y; Ritter DI; Wang J; Oh C; Paczkowska M; Reynolds S; Wyczalkowski MA; Oak N
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
Cell Volume: 173 Page(s): 386 - 399.e12
04/05/2018 Authors: Chen H; Li C; Peng X; Zhou Z; Weinstein JN; Cancer Genome Atlas Research Network; Liang H
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
Cell Volume: 173 Page(s): 338 - 354.e15
04/05/2018 Authors: Malta TM; Sokolov A; Gentles AJ; Burzykowski T; Poisson L; Weinstein JN; Kamiska B; Huelsken J; Omberg L; Gevaert O
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Cell Volume: 173 Page(s): 321 - 337.e10
04/05/2018 Authors: Sanchez-Vega F; Mina M; Armenia J; Chatila WK; Luna A; La KC; Dimitriadoy S; Liu DL; Kantheti HS; Saghafinia S
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell Volume: 173 Page(s): 371 - 385.e18
04/05/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell Volume: 173 Page(s): 400 - 416.e11
04/05/2018 Authors: Liu J; Lichtenberg T; Hoadley KA; Poisson LM; Lazar AJ; Cherniack AD; Kovatich AJ; Benz CC; Levine DA; Lee AV
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Cell Rep Volume: 23 Page(s): 227 - 238.e3
04/03/2018 Authors: Gao Q; Liang W-W; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao W-W; Reynolds SM; Wyczalkowski MA; Yao L
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
Cell Rep Volume: 23 Page(s): 297 - 312.e12
04/03/2018 Authors: Chiu H-S; Somvanshi S; Patel E; Chen T-W; Singh VP; Zorman B; Patil SL; Pan Y; Chatterjee SS; Cancer Genome Atlas Research Network
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Cell Rep Volume: 23 Page(s): 313 - 326.e5
04/03/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
Cell Rep Volume: 23 Page(s): 255 - 269.e4
04/03/2018 Authors: Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Cell Rep Volume: 23 Page(s): 194 - 212.e6
04/03/2018 Authors: Campbell JD; Yau C; Bowlby R; Liu Y; Brennan K; Fan H; Taylor AM; Wang C; Walter V; Akbani R
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Cell Rep Volume: 23 Page(s): 213 - 226.e3
04/03/2018 Authors: Ge Z; Leighton JS; Wang Y; Peng X; Chen Z; Chen H; Sun Y; Yao F; Li J; Zhang H
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
Cell Rep Volume: 23 Page(s): 181 - 193.e7
04/03/2018 Authors: Saltz J; Gupta R; Hou L; Kurc T; Singh P; Nguyen V; Samaras D; Shroyer KR; Zhao T; Batiste R
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Cell Rep Volume: 23 Page(s): 172 - 180.e3
04/03/2018 Authors: Way GP; Sanchez-Vega F; La K; Armenia J; Chatila WK; Luna A; Sander C; Cherniack AD; Mina M; Ciriello G
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
Cell Rep Volume: 23 Page(s): 282 - 296.e4
04/03/2018 Authors: Seiler M; Peng S; Agrawal AA; Palacino J; Teng T; Zhu P; Smith PG; Cancer Genome Atlas Research Network; Buonamici S; Yu L
Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Cell Rep Volume: 23 Page(s): 270 - 281.e3
04/03/2018 Authors: Jayasinghe RG; Cao S; Gao Q; Wendl MC; Vo NS; Reynolds SM; Zhao Y; Climente-Gonzlez H; Chai S; Wang F
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Cell Rep Volume: 23 Page(s): 239 - 254.e6
04/03/2018 Authors: Knijnenburg TA; Wang L; Zimmermann MT; Chambwe N; Gao GF; Cherniack AD; Fan H; Shen H; Way GP; Greene CS
The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery.
Bioinformatics Volume: 34 Page(s): 1183 - 1191
04/01/2018 Authors: Ivanov AA; Revennaugh B; Rusnak L; Gonzalez-Pecchi V; Mo X; Johns MA; Du Y; Cooper LAD; Moreno CS; Khuri FR
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
Cell Syst Volume: 6 Page(s): 271 - 281.e7
03/28/2018 Authors: Ellrott K; Bailey MH; Saksena G; Covington KR; Kandoth C; Stewart C; Hess J; Ma S; Chiotti KE; McLellan M
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Cell Syst Volume: 6 Page(s): 282 - 300.e2
03/28/2018 Authors: Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Mol Cell Volume: 69 Page(s): 923 - 937.e8
03/15/2018 Authors: Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang H-B; Pan Y; Liu S
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Cancer Volume: 124 Page(s): 271 - 277
01/15/2018 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.
Mol Cell Volume: 69 Page(s): 87 - 99.e7
01/04/2018 Authors: Jin L; Chun J; Pan C; Kumar A; Zhang G; Ha Y; Li D; Alesi GN; Kang Y; Zhou L
California dreaming.
Cancer Volume: 123 Page(s): 4528 - 4529
12/01/2017 Authors: Khuri FR
Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States
Volume: 12 Page(s): S2325 - S2326
11/01/2017 Authors: Behera M; Jiang R; Higgins K; Pillai R; Owonikoko T; Belani C; Khuri F; Ward K; Curran W; Ramalingam S
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Cancer Volume: 123 Page(s): 4099 - 4105
11/01/2017 Authors: Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence.
Cancer Prev Res (Phila) Volume: 10 Page(s): 635 - 640
11/01/2017 Authors: Belinsky SA; Leng S; Wu G; Thomas CL; Picchi MA; Lee SJ; Aisner S; Ramalingam S; Khuri FR; Karp DD
OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc.
Oncogene Volume: 36 Page(s): 5852 - 5860
10/19/2017 Authors: Ivanov AA; Gonzalez-Pecchi V; Khuri LF; Niu Q; Wang Y; Xu Y; Bai Y; Mo X; Prochownik EV; Johns MA
Gene methylation biomarkers in sputum as a classifier for lung cancer risk.
Oncotarget Volume: 8 Page(s): 63978 - 63985
09/08/2017 Authors: Leng S; Wu G; Klinge DM; Thomas CL; Casas E; Picchi MA; Stidley CA; Lee SJ; Aisner S; Siegfried JM
Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status.
Oncotarget Volume: 8 Page(s): 59008 - 59022
08/29/2017 Authors: Zhang J; Nannapaneni S; Wang D; Liu F; Wang X; Jin R; Liu X; Rahman MA; Peng X; Qian G
A better angel of our nature: Hanna Michel "Jean" Khoury, MD (April 24, 1967-May 22, 2017).
Cancer Volume: 123 Page(s): 2998 - 3002
08/15/2017 Authors: Khuri FR
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
JAMA Oncol Volume: 3 Page(s): 1120 - 1129
08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ
Gene methylation biomarkers in sputum as a classifier for lung cancer risk.
Oncotarget
07/15/2017 Authors: Leng S; Wu G; Klinge DM; Thomas CL; Casas E; Picchi MA; Stidley CA; Lee SJ; Aisner S; Siegfried JM
Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis.
Oncogene Volume: 36 Page(s): 3797 - 3806
07/06/2017 Authors: Jin L; Chun J; Pan C; Alesi GN; Li D; Magliocca KR; Kang Y; Chen ZG; Shin DM; Khuri FR
Modulation of Bax and mTOR for cancer therapeutics
Volume: 77
07/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W
Gene methylation biomarkers in sputum as a classifier for lung cancer risk
Volume: 77
07/01/2017 Authors: Picchi MA; Leng S; Wu G; Klinge DM; Thomas CL; Casas E; Stidley CA; Lee SJ; Aisner S; Siegfried JM
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
J Biol Chem Volume: 292 Page(s): 10142 - 10152
06/16/2017 Authors: Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang H-B; Arbiser JL; Pollack BP
Modulation of Bax and mTOR for Cancer Therapeutics.
Cancer Res Volume: 77 Page(s): 3001 - 3012
06/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W
Early proliferation of PD-1+CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC
Volume: 35
05/20/2017 Authors: Pillai RN; Kamphorst A; Yang S; Owonikoko TK; Sica G; Nasti T; Akondy R; Wieland A; Wu H; Patel N
Optimal thoracic radiation dose in limited stage small cell lung cancer.
Volume: 35
05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C
Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
Volume: 35
05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Proc Natl Acad Sci U S A Volume: 114 Page(s): 4993 - 4998
05/09/2017 Authors: Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT
Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell LungCancer.
Clin Lung Cancer Volume: 18 Page(s): e203 - e210
05/01/2017 Authors: Saba NF; Wang Y; Fu H; Koenig L; Khuri FR; Shin DM; Chen ZG
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Volume: 18 Page(s): 286 - 292
05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK
Corrigendum: The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.
Nat Commun Volume: 8 Page(s): 15350
04/18/2017 Authors: Li Z; Ivanov AA; Su R; Gonzalez-Pecchi V; Qi Q; Liu S; Webber P; McMillan E; Rusnak L; Pham C
AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay.
Mol Pharmacol Volume: 91 Page(s): 339 - 347
04/01/2017 Authors: Mo X; Qi Q; Ivanov AA; Niu Q; Luo Y; Havel J; Goetze R; Bell S; Moreno CS; Cooper LAD
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.
JCI Insight Volume: 2 Page(s): e90487
03/09/2017 Authors: Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH
Five more years! Not everything changes.
Cancer Volume: 123 Page(s): 724 - 727
03/01/2017 Authors: Khuri FR
The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.
Nat Commun Volume: 8 Page(s): 14356
02/16/2017 Authors: Li Z; Ivanov AA; Su R; Gonzalez-Pecchi V; Qi Q; Liu S; Webber P; McMillan E; Rusnak L; Pham C
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.
Cell Metab Volume: 25 Page(s): 358 - 373
02/07/2017 Authors: Xia S; Lin R; Jin L; Zhao L; Kang H-B; Pan Y; Liu S; Qian G; Qian Z; Konstantakou E
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Clin Cancer Res Volume: 23 Page(s): 677 - 686
02/01/2017 Authors: Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin ARMR; Rossi M; Patel M; El-Deiry M; Wadsworth JT
Financial burden of cancer drug treatment in Lebanon
Volume: 72 Page(s): S117 - S117
02/01/2017 Authors: Elias F
Integrated genomic characterization of oesophageal carcinoma.
Nature Volume: 541 Page(s): 169 - 175
01/12/2017 Authors: Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Womens Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
Oncogene Volume: 36 Page(s): 254 - 262
01/12/2017 Authors: Elf S; Lin R; Xia S; Pan Y; Shan C; Wu S; Lonial S; Gaddh M; Arellano ML; Khoury HJ
Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Volume: 12 Page(s): S470 - S470
01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R
Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Volume: 12 Page(s): S253 - S254
01/01/2017 Authors: Pillai R; Behera M; Owonikoko T; Kamphorst A; Pakkala S; Belani C; Khuri F; Ahmed R; Ramalingam S
Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
Volume: 12 Page(s): S703 - S704
01/01/2017 Authors: Kim S; Ragin C; Chen Z; Behera M; Pillai R; Steuer C; Belani C; Khuri F; Ramalingam S; Owonikoko T
The known unknown.
Cancer Volume: 123 Page(s): 17 - 19
01/01/2017 Authors: Khuri FR
MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.
PLoS One Volume: 12 Page(s): e0170339
01/01/2017 Authors: Harati S; Cooper LAD; Moran JD; Giuste FO; Du Y; Ivanov AA; Johns MA; Khuri FR; Fu H; Moreno CS
National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys Volume: 97 Page(s): 128 - 137
01/01/2017 Authors: Higgins KA; O'Connell K; Liu Y; Gillespie TW; McDonald MW; Pillai RN; Patel KR; Patel PR; Robinson CG; Simone CB
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
Mol Cell Volume: 64 Page(s): 859 - 874
12/01/2016 Authors: Fan J; Lin R; Xia S; Chen D; Elf SE; Liu S; Pan Y; Xu H; Qian Z; Wang M
RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis.
Oncogene Volume: 35 Page(s): 5412 - 5421
10/13/2016 Authors: Alesi GN; Jin L; Li D; Magliocca KR; Kang Y; Chen ZG; Shin DM; Khuri FR; Kang S
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.
Volume: 17 Page(s): e57 - e64
09/01/2016 Authors: Behera M; Owonikoko TK; Gal AA; Steuer CE; Kim S; Pillai RN; Khuri FR; Ramalingam SS; Sica GL
[Not Available].
Thyroid Volume: 26 Suppl 1 Page(s): A138 - A163
09/01/2016
Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance.
Mol Cancer Res Volume: 14 Page(s): 675 - 682
08/01/2016 Authors: Cancer Target Discovery and Development Network
Developing a personalized anti-metastatic therapy to treat KRAS, LKB1-mutant lung adenocarcinoma
Volume: 76
07/01/2016 Authors: Gilbert-Ross M; Konen J; Koo J; Shupe J; Sica GL; Chen Z; Robinson BS; Behera M; Rossi MR; Smith GH
The regulation of pre-ribosomal RNA synthesis by LKB1
Volume: 76
07/01/2016 Authors: Jin R; Liu F; Liu X; Huang H; Wilkinson SC; Zhong D; Khuri FR; Fu H; Marcus AI; He Y
HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models
Volume: 76
07/01/2016 Authors: Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Chen Z; Patel MR; El-Deiry MW; Wadsworth JT; Shin DM
Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.
J Mol Cell Biol Volume: 8 Page(s): 271 - 281
06/01/2016 Authors: Mo X-L; Luo Y; Ivanov AA; Su R; Havel JJ; Li Z; Khuri FR; Du Y; Fu H
Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy.
Head Neck Volume: 38 Page(s): 846 - 851
06/01/2016 Authors: Hanasoge S; Magliocca KR; Switchenko JM; Saba NF; Wadsworth JT; El-Deiry MW; Shin DM; Khuri F; Beitler JJ; Higgins KA
Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
Volume: 34
05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN
National Cancer Data Base analysis of proton versus photon radiotherapy in non-small cell lung cancer(NSCLC).
Volume: 34
05/20/2016 Authors: Behera M; OConnell KA; Liu Y; Gillespie TW; Pillai RN; Patel P; Simone CB; Robinson CG; Owonikoko TK; Belani CP
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
Volume: 34
05/20/2016 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Role of anti-EGFR monoclonal antibody in EGFR FISH positive NSCLC patients: A meta-analysis of phase III randomized controlled trials.
Volume: 34
05/20/2016 Authors: Patel N; Behera M; Pillai RN; Owonikoko TK; Pakkala S; Belani CP; Khuri FR; Ramalingam SS
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
J Transl Med Volume: 14 Page(s): 111
05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R
Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
Support Care Cancer Volume: 24 Page(s): 1789 - 1793
04/01/2016 Authors: McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
An early treatment window to target FAK-dependent collective invasion in Lkb1-mutant lung adenocarcinoma
Volume: 76
04/01/2016 Authors: Gilbert-Ross M; Konen J; Shupe J; Koo J; Sica GL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis
Volume: 76
04/01/2016 Authors: Alesi G; Jin L; Li D; Magliocca K; Kang Y; Chen ZG; Shin DM; Khuri FR; Kang S
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
J Mol Diagn Volume: 18 Page(s): 299 - 315
03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Cancer Volume: 122 Page(s): 766 - 772
03/01/2016 Authors: Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
Oncogene Volume: 35 Page(s): 642 - 650
02/04/2016 Authors: Li S; Oh Y-T; Yue P; Khuri FR; Sun S-Y
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Oncogene Volume: 35 Page(s): 459 - 467
01/28/2016 Authors: Oh Y-T; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun S-Y
LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions.
Oncotarget Volume: 7 Page(s): 2519 - 2531
01/19/2016 Authors: Liu F; Jin R; Liu X; Huang H; Wilkinson SC; Zhong D; Khuri FR; Fu H; Marcus A; He Y
Financial Burden of Cancer Drug Treatment in Lebanon.
Asian Pac J Cancer Prev Volume: 17 Page(s): 3173 - 3177
01/01/2016 Authors: Elias F; Khuri FR; Adib SM; Karam R; Harb H; Awar M; Zalloua P; Ammar W
Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation.
J Oncol Pract Volume: 12 Page(s): 55 - 58
01/01/2016 Authors: Ostroff JS; Goffin JR; Khuri FR; Warren GW
Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.
Cancer Prev Res (Phila) Volume: 9 Page(s): 63 - 73
01/01/2016 Authors: Anisuzzaman ASM; Haque A; Rahman MA; Wang D; Fuchs JR; Hurwitz S; Liu Y; Sica G; Khuri FR; Chen ZG
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
Cancer Volume: 122 Page(s): 50 - 60
01/01/2016 Authors: Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS
Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Volume: 1 Page(s): 1293 - 1300
12/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.
Oncotarget Volume: 6 Page(s): 41324 - 41338
12/01/2015 Authors: Oh Y-T; Yue P; Wang D; Tong J-S; Chen ZG; Khuri FR; Sun S-Y
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Nat Cell Biol Volume: 17 Page(s): 1484 - 1496
11/01/2015 Authors: Lin R; Elf S; Shan C; Kang H-B; Ji Q; Zhou L; Hitosugi T; Zhang L; Zhang S; Seo JH
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Oncotarget Volume: 6 Page(s): 34669 - 34679
10/27/2015 Authors: Yao W; Yue P; Khuri FR; Sun S-Y
Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
Cancer Volume: 121 Page(s): 3600 - 3611
10/15/2015 Authors: Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR
Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Oncotarget Volume: 6 Page(s): 30773 - 30786
10/13/2015 Authors: Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Pain Intensity and Pain Interference in Patients With Lung Cancer: A Pilot Study of Biopsychosocial Predictors.
Am J Clin Oncol Volume: 38 Page(s): 457 - 464
10/01/2015 Authors: Dalton JA; Higgins MK; Miller AH; Keefe FJ; Khuri FR
15TH INTERNATIONAL THYROID CONGRESS PROGRAM AND MEETING ABSTRACTS.
Thyroid Volume: 25 Suppl 1 Page(s): P1 - A337
10/01/2015
Modernizing Eligibility Criteria for Molecularly Driven Trials.
J Clin Oncol Volume: 33 Page(s): 2815 - 2820
09/01/2015 Authors: Kim ES; Bernstein D; Hilsenbeck SG; Chung CH; Dicker AP; Ersek JL; Stein S; Khuri FR; Burgess E; Hunt K
Business as usual is not acceptable.
Cancer Volume: 121 Page(s): 2864 - 2865
09/01/2015 Authors: Cummings KM; Gustafson JW; Sales DJ; Khuri FR; Warren GW
Early detection of lung cancer in China: The immediate imperative.
Cancer Volume: 121 Suppl 17 Page(s): 3055 - 3057
09/01/2015 Authors: Veeraraghavan S; Ramalingam SS; Khuri FR
Lung cancer in China: The new frontier?
Cancer Volume: 121 Suppl 17 Page(s): 3058 - 3060
09/01/2015 Authors: Ramalingam SS; Khuri FR
Tobacco and China: The worst is yet to come.
Cancer Volume: 121 Suppl 17 Page(s): 3052 - 3054
09/01/2015 Authors: Paskett ED; Bernardo BM; Khuri FR
An overview of Cancer's special issue on lung cancer in China.
Cancer Volume: 121 Suppl 17 Page(s): 3049 - 3051
09/01/2015 Authors: Khuri FR
Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB)
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S367 - S367
09/01/2015 Authors: Behera M; Owonikoko TK; Liu Y; Gillespie TW; Yuan M; Pillai RN; Steuer C; Higgins KA; Pakkala S; Belani CP
A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP
Survival Impact of Adjuvant Radiation and Chemotherapy in Patients with Typical and Atypical Pulmonary Carcinoids
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S507 - S507
09/01/2015 Authors: Hannan LM; Switchenko J; Liu Y; Behera M; Higgins KA; Fernandez F; Pillai RN; Khuri F; Ramalingam SS; Gillespie TW
Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S545 - S545
09/01/2015 Authors: Kumar M; Ragin C; Zhang C; Chen Z; Han EJ; Ernani V; Behera M; Steuer C; Saba N; Shin D
A Titan exits stage left: Summary of the Waun Ki Hong Festschrift.
Cancer Volume: 121 Page(s): 2849 - 2851
08/15/2015 Authors: Khuri FR
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Mol Cell Volume: 59 Page(s): 345 - 358
08/06/2015 Authors: Kang H-B; Fan J; Lin R; Elf S; Ji Q; Zhao L; Jin L; Seo JH; Shan C; Arbiser JL
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ann Oncol Volume: 26 Page(s): 1741 - 1748
08/01/2015 Authors: Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F
Development of Bcl2 BH4 antagonist for cancer therapy
Volume: 75
08/01/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko T; Sica G; Ding C; Zhou J; Magis A; Ramalingam S
Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients
Volume: 75
08/01/2015 Authors: Kamphorst AO; Pillai RN; Yang S; Akondy R; Koenig L; Yu K; McCausland M; Sica G; Khuri FR; Owonikoko TK
Potent curcumin analog FLLL12 induces apoptosis in lung cancer cells through death receptor-5-dependent pathway
Volume: 75
08/01/2015 Authors: Haque A; Rahman MA; Fuchs JR; Clien ZG; Khuri FR; Shin DM; Amin ARMR
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Cancer Lett Volume: 364 Page(s): 70 - 78
08/01/2015 Authors: Yao W; Yue P; Zhang G; Owonikoko TK; Khuri FR; Sun S-Y
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth
Volume: 75
08/01/2015 Authors: Jin L; Li D; Alesi G; Fan J; Kang H-B; Zhou L; Boggon T; Magliocca K; He C; Arellano M
A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
Volume: 75
08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
J Thorac Oncol Volume: 10 Page(s): 1142 - 1147
08/01/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clin Proc Volume: 90 Page(s): 996 - 1000
08/01/2015 Authors: Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC
FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway.
Cancer Lett Volume: 363 Page(s): 166 - 175
07/28/2015 Authors: Haque A; Rahman MA; Fuchs JR; Chen ZG; Khuri FR; Shin DM; Amin ARMR
Time to divest from tobacco-funded research.
Cancer Volume: 121 Page(s): 2294 - 2295
07/15/2015 Authors: Khuri FR; Ramalingam SS
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Oncotarget Volume: 6 Page(s): 17532 - 17542
07/10/2015 Authors: Han B; Yao W; Oh Y-T; Tong J-S; Li S; Deng J; Yue P; Khuri FR; Sun S-Y
Can we achieve an 80% screening rate for colorectal cancer by 2018 in the United States?
Cancer Volume: 121 Page(s): 2127 - 2128
07/01/2015 Authors: Paskett ED; Khuri FR
Development and testing of a tool to assess patient preferences for phase I clinical trial participation.
Psychooncology Volume: 24 Page(s): 835 - 838
07/01/2015 Authors: Pentz RD; Hendershot KA; Wall L; White TE; Peterson SK; Thomas CB; McCormick J; Green MJ; Lewis C; Farmer ZL
Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
Apoptosis Volume: 20 Page(s): 986 - 995
07/01/2015 Authors: Haque A; Rahman MA; Chen ZG; Saba NF; Khuri FR; Shin DM; Ruhul Amin ARM
mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
Mol Cell Biol Volume: 35 Page(s): 2344 - 2355
07/01/2015 Authors: Koo J; Yue P; Deng X; Khuri FR; Sun S-Y
Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Contemp Clin Trials Volume: 43 Page(s): 133 - 141
07/01/2015 Authors: Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Genomic Classification of Cutaneous Melanoma.
Cell Volume: 161 Page(s): 1681 - 1696
06/18/2015 Authors: Cancer Genome Atlas Network
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Cancer Cell Volume: 27 Page(s): 852 - 863
06/08/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT
Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis.
Oral Oncol Volume: 51 Page(s): 586 - 592
06/01/2015 Authors: Joseph LJ; Goodman M; Higgins K; Pilai R; Ramalingam SS; Magliocca K; Patel MR; El-Deiry M; Wadsworth JT; Owonikoko TK
Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
J Biol Chem Volume: 290 Page(s): 14120 - 14129
05/29/2015 Authors: Koo J; Wu X; Mao Z; Khuri FR; Sun S-Y
Comparative genomics of pulmonary and extrapulmonary small cell carcinoma.
Volume: 33
05/20/2015 Authors: Sica G; Hanley K; Newman S; Mosunjac M; Martinez A; Han E; Zhang G; Ramalingam SS; Khuri FR; Rossi MR
Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data
Volume: 33
05/20/2015 Authors: Saba NF; Newman S; Rossi MR; Steuer CE; Zhang H; Patel M; Wadsworth JT; El-Deiry M; Magliocca KR; Owonikoko TK
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
Volume: 33
05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S
Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models.
Volume: 33
01/01/2015 Authors: Saba NF; Wang D; Qian G; Zhang H; Patel M; El-Deiry M; Wadsworth JT; Magliocca KR; Nannapaneni S; Shin DM
Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
Volume: 33
05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS
PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer.
Volume: 33
05/20/2015 Authors: Owonikoko TK; Kowalski J; Kim S; Dwivedi B; Chen Z; Behera M; Mayfield W; Hermann RC; Chen L; Khuri FR
Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
Volume: 33
05/20/2015 Authors: Owonikoko TK; Nelson M; Park SY; Kim S; Steuer CE; Behera M; Chen Z; Han E; Kumar M; Ernani V
Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.
Oncogene Volume: 34 Page(s): 2538 - 2545
05/07/2015 Authors: Shi Z; Li Z; Li ZJ; Cheng K; Du Y; Fu H; Khuri FR
Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Lung Cancer Volume: 88 Page(s): 131 - 138
05/01/2015 Authors: Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Oncotarget Volume: 6 Page(s): 8974 - 8987
04/20/2015 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
Cancer Volume: 121 Page(s): E1 - E6
04/15/2015 Authors: Steuer CE; Khuri FR; Ramalingam SS
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD
Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis.
Lung Cancer Volume: 88 Page(s): 80 - 84
04/01/2015 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai R; Saba NF; Shin DM; Owonikoko TK; Khuri FR
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis.
J Thorac Oncol Volume: 10 Page(s): 479 - 485
03/01/2015 Authors: Steuer CE; Behera M; Kim S; Chen Z; Saba NF; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.
J Thorac Oncol Volume: 10 Page(s): 462 - 471
03/01/2015 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
Ther Adv Med Oncol Volume: 7 Page(s): 56 - 62
03/01/2015 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z; Rossi MR; Adsay NV
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
Cancer Cell Volume: 27 Page(s): 257 - 270
02/09/2015 Authors: Jin L; Li D; Alesi GN; Fan J; Kang H-B; Lu Z; Boggon TJ; Jin P; Yi H; Wright ER
Lung
Page(s): 205 - 220
01/01/2015 Authors: Ramalingam SS; Fernandez F; Higgins KA; Auffermann WF; Khuri FR
Cables1 complex couples survival signaling to the cell death machinery.
Cancer Res Volume: 75 Page(s): 147 - 158
01/01/2015 Authors: Shi Z; Park HR; Du Y; Li Z; Cheng K; Sun S-Y; Li Z; Fu H; Khuri FR
What we know and what we think we know: an editor's perspective on a charged debate.
Cancer Volume: 121 Page(s): 4 - 5
01/01/2015 Authors: Khuri FR
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Oncoscience Volume: 2 Page(s): 765 - 776
01/01/2015 Authors: Webber PJ; Park C; Qui M; Ramalingam SS; Khuri FR; Fu H; Du Y
Curcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathways.
PLoS One Volume: 10 Page(s): e0124218
01/01/2015 Authors: Amin ARMR; Haque A; Rahman MA; Chen ZG; Khuri FR; Shin DM
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Cancer Volume: 120 Page(s): 3940 - 3951
12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Cancer Med Volume: 3 Page(s): 1579 - 1594
12/01/2014 Authors: Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM
Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis
Volume: 90 Page(s): S50 - S51
11/15/2014 Authors: Steuer C; Behera M; Rossi M; Fisher K; Sica G; Gal A; Pakkala S; Pillai R; Owonikoko T; Khuri F
Clinical and Pathologic Characterization of Folate Receptor Alpha, Mesothelin, and Endosialin Expression in Mesotheliomas
Volume: 90 Page(s): S29 - S29
11/15/2014 Authors: Owonikoko TK; Busari A; Chen Z; Kim S; Alexis D; Somers EB; O'Shannessy DJ; Ramalingam S; Khuri F; Sica GL
Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia
Volume: 90 Page(s): S62 - S62
11/15/2014 Authors: Kazi HA; Behera M; Steuer C; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
Higher Dose of Palliative Thoracic Radiation Is Associated With Improved Survival for Patients With Stage IV Non-Small Cell Lung Cancer
Volume: 90 Page(s): S48 - S48
11/15/2014 Authors: Rajpara RS; Gillespie TW; Nickleach DC; Liu Y; Lipscomb J; Fernandez FG; Mikell JL; Ramalingam SS; Owonikoko TK; Pillai RN
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S68 - S69
11/15/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
Postoperative Radiation Therapy (PORT) Is Associated With Better Survival in Non-Small Cell Lung Cancer With Involved N2 Lymph Nodes
Volume: 90 Page(s): S18 - S18
11/15/2014 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG
Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J
Integrated genomic characterization of papillary thyroid carcinoma.
Cell Volume: 159 Page(s): 676 - 690
10/23/2014 Authors: Cancer Genome Atlas Research Network
Restoration of LKB1 defect in EKVX cells leads to resistance to microtubule targeting agents
Volume: 74
10/01/2014 Authors: Mao K; Liu F; Liu X; He Y; Khuri F; Marcus A; Li M; Zhou W
Pharmacological inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs cancer cell response to DR5 activation-induced apoptosis
Volume: 74
10/01/2014 Authors: Oh Y-T; Yue P; Owonikoko TK; Khuri FR; Sun S-Y
RSK2-mediated phosphorylation of stathmin promotes microtubule polymerization, providing a pro-invasive advantage to metastatic cancer cells
Volume: 74
10/01/2014 Authors: Alesi G; Li D; Jin L; Chen GZ; Shin DM; Khuri F; Kang S
Development of small molecule Bax agonists for lung cancer treatment
Volume: 74
10/01/2014 Authors: Xin M; Li R; Park D; Owonikoko TK; Sica GL; Corsino PE; Ding JZC; Magis AT; Ramalingam SS; Curran WJ
Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer
Volume: 74
10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Kim HS; Ogee-Nwankwo OC; Ramalingam SS; Rossi MR; Khuri FR
Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer
Volume: 74
10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Chen Z; Switchenko JM; Kim S; Gal AA; Ramalingam SS; Deng X; Rossi MR
mTOR complex 2 (mTORC2) positively regulates Mcl-1 stability by suppressing GSK3-dependent and FBXW7-mediated proteasomal degradation of Mcl-1
Volume: 74
10/01/2014 Authors: Koo J; Yue P; Khuri FR; Sun S-Y
Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.
J Biol Chem Volume: 289 Page(s): 26533 - 26541
09/19/2014 Authors: Fan J; Kang H-B; Shan C; Elf S; Lin R; Xie J; Gu T-L; Aguiar M; Lonning S; Chung T-W
Small-molecule Bax agonists for cancer therapy.
Nat Commun Volume: 5 Page(s): 4935
09/17/2014 Authors: Xin M; Li R; Xie M; Park D; Owonikoko TK; Sica GL; Corsino PE; Zhou J; Ding C; White MA
Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review.
Oral Oncol Volume: 50 Page(s): 888 - 894
09/01/2014 Authors: Behera M; Owonikoko TK; Kim S; Chen Z; Higgins K; Ramalingam SS; Shin DM; Khuri FR; Beitler JJ; Saba NF
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S80 - S81
09/01/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
EVALUATION OF HOSPITALIZATION TRENDS IN LUNG CANCER PATIENTS WITH HYPONATREMIA
JOURNAL OF THORACIC ONCOLOGY Volume: 9 Page(s): S182 - S182
09/01/2014 Authors: Kazi HA; Behera M; Steuer C; Owonikoko T; Pillai R; Ramalingam SS; Khuri FR
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Mol Cell Volume: 55 Page(s): 552 - 565
08/21/2014 Authors: Shan C; Elf S; Ji Q; Kang H-B; Zhou L; Hitosugi T; Jin L; Lin R; Zhang L; Seo JH
Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth.
J Biol Chem Volume: 289 Page(s): 21413 - 21422
08/01/2014 Authors: Shan C; Kang H-B; Elf S; Xie J; Gu T-L; Aguiar M; Lonning S; Hitosugi T; Chung T-W; Arellano M
Targeted therapies in metastatic esophageal cancer: advances over the past decade.
Crit Rev Oncol Hematol Volume: 91 Page(s): 186 - 196
08/01/2014 Authors: Mohamed A; El-Rayes B; Khuri FR; Saba NF
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Mol Cancer Ther Volume: 13 Page(s): 1826 - 1836
07/01/2014 Authors: Jiang N; Wang D; Hu Z; Shin HJC; Qian G; Rahman MA; Zhang H; Amin ARMR; Nannapaneni S; Wang X
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
Cell Death Differ Volume: 21 Page(s): 1160 - 1169
07/01/2014 Authors: Wang B; Xie M; Li R; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Wang Y; Deng X
Second-generation ALK inhibitors: filling the non "MET" gap.
Cancer Discov Volume: 4 Page(s): 634 - 636
06/01/2014 Authors: Ramalingam SS; Khuri FR
HPV-associated lung cancers: an international pooled analysis.
Carcinogenesis Volume: 35 Page(s): 1267 - 1275
06/01/2014 Authors: Ragin C; Obikoya-Malomo M; Kim S; Chen Z; Flores-Obando R; Gibbs D; Koriyama C; Aguayo F; Koshiol J; Caporaso NE
Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs.
Oncotarget Volume: 5 Page(s): 3197 - 3209
05/30/2014 Authors: Li Z; Park HR; Shi Z; Li Z; Pham CD; Du Y; Khuri FR; Zhang Y; Han Q; Fu H
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
JAMA Volume: 311 Page(s): 1998 - 2006
05/21/2014 Authors: Kris MG; Johnson BE; Berry LD; Kwiatkowski DJ; Iafrate AJ; Wistuba II; Varella-Garcia M; Franklin WA; Aronson SL; Su P-F
Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.
Volume: 32
05/20/2014 Authors: Steuer CE; Behera M; Kim S; Chen Z; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.
Volume: 32
05/20/2014 Authors: Behera M; Steuer CE; Kim S; Pillai RN; Chen Z; Owonikoko TK; Belani CP; Khuri FR; Ramalingam SS
Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy
Volume: 32
05/20/2014 Authors: Behera M; Ragin C; Kim S; Chen Z; Steuer CE; Saba NF; Pillal RN; Belani CP; Ramalingam SS; Khuri FR
Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.
Volume: 32
05/20/2014 Authors: Joseph L; Goodman M; Higgins KA; Pilai R; Ramalingam SS; Owonikoko TK; Beitler JJ; Shin DM; Khuri FR; Saba NF
Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to cheinoprevention with EGFR and COX-2 inhibitors.
Volume: 32
05/20/2014 Authors: Saba NF; Rossi MR; Dwivedi B; Switchenko JM; Magllocca KR; Ramalingam SS; Owonlkoko TK; Khuri FR; Chen ZG; Kowalski J
Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis
Volume: 32
05/20/2014 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai RN; Saba NF; Shin DM; Owonlkoko TK; Khuri FR
Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC).
Volume: 32
05/20/2014 Authors: Saba NF; Qian G; Ning J; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG
Second primary lung cancers: Analysis of E5597 selenium chemoprevention study.
Volume: 32
05/20/2014 Authors: Pillai RN; Lee SJ; Karp DD; Aisner SC; Ruckdeschel JC; Ramalingam SS; Khuri FR
Standardizing measurement of tobacco use in cancer clinical trials
Volume: 32
05/20/2014 Authors: Land SR; Toll B; Warren GW; Brandon TH; Mitchell SA; Dresler CM; Gritz ER; Schnoll R; Sarna L; Moinpour C
Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.
Volume: 32
05/20/2014 Authors: Zhang J; Wang D; Qian G; Liu F; Rahman MA; Nannapaneni S; Wang X; Peng X; Chen ZG; Wong K-K
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
Cancer Volume: 120 Page(s): 1394 - 1400
05/01/2014 Authors: Kang H; Gillespie TW; Goodman M; Brodie SA; Brandes M; Ribeiro M; Ramalingam SS; Shin DM; Khuri FR; Brandes JC
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
Cancer Res Volume: 74 Page(s): 2555 - 2568
05/01/2014 Authors: Koo J; Yue P; Gal AA; Khuri FR; Sun S-Y
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer Volume: 120 Page(s): 1145 - 1154
04/15/2014 Authors: Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D
AACR celebrates 50 years of tobacco research and policy.
Clin Cancer Res Volume: 20 Page(s): 1709 - 1718
04/01/2014 Authors: Herbst RS; Hobin JA; Gritz ER; Writing Committee for the AACR Subcommittee on Tobacco and Cancer
Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.
Cancer Prev Res (Phila) Volume: 7 Page(s): 351 - 361
03/01/2014 Authors: Brodie SA; Li G; El-Kommos A; Kang H; Ramalingam SS; Behera M; Gandhi K; Kowalski J; Sica GL; Khuri FR
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Head Neck Pathol Volume: 8 Page(s): 66 - 72
03/01/2014 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ
Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Contemp Clin Trials Volume: 37 Page(s): 322 - 332
03/01/2014 Authors: Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Cancer Prev Res (Phila) Volume: 7 Page(s): 283 - 291
03/01/2014 Authors: Saba NF; Hurwitz SJ; Kono SA; Yang CS; Zhao Y; Chen Z; Sica G; Mller S; Moreno-Williams R; Lewis M
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.
Mol Cell Volume: 53 Page(s): 534 - 548
02/20/2014 Authors: Fan J; Shan C; Kang H-B; Elf S; Xie J; Tucker M; Gu T-L; Aguiar M; Lonning S; Chen H
Of Gdansk and glass houses.
Cancer Volume: 120 Page(s): 612 - 613
02/15/2014 Authors: Khuri FR
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
Thyroid Volume: 24 Page(s): 232 - 240
02/01/2014 Authors: Sosa JA; Elisei R; Jarzab B; Balkissoon J; Lu S-P; Bal C; Marur S; Gramza A; Yosef RB; Gitlitz B
SOX2 Expression in EGFR and KRAS Mutated Lung Adenocarcinomas
Volume: 27 Page(s): 476A - 476A
02/01/2014 Authors: Fatima N; Fisher K; Rossi MR; Zhang L; Owanikoko T; Ramalingam S; Khuri F; Gal A; Cohen C; Sica G
c-Met Immunohistochemistry in EGFR Mutant Adenocarcinoma: Comparison with Fluorescence In-Situ Hybridization
Volume: 27 Page(s): 499A - 499A
02/01/2014 Authors: Willis BC; Martin DR; Saxe D; Ramalingam SS; Khuri F; Fisher KE; Rossi MR; Cohen C; Sica G
c-Met Immunohistochemistry in EGFR Mutant Adenocarcinoma: Comparison with Fluorescence In-Situ Hybridization
Volume: 94 Page(s): 499A - 499A
02/01/2014 Authors: Willis BC; Mortin DR; Saxe D; Ramalingam SS; Khuri F; Fisher KE; Rossi MR; Cohen C; Sica G
SOX2 Expression in EGFR and KRAS Mutated Lung Adenocarcinomas
Volume: 94 Page(s): 476A - 476A
02/01/2014 Authors: Fatima N; Fisher K; Rossi MR; Zhang L; Owanikoko T; Ramalingam S; Khuri F; Gal A; Cohen C; Sica G
Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
Volume: 27 Page(s): 476A - 477A
02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL
Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
Volume: 94 Page(s): 476A - 477A
02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL
The first Surgeon General's report on smoking and health: the 50th anniversary.
CA Cancer J Clin Volume: 64 Page(s): 5 - 8
01/01/2014 Authors: Brawley OW; Glynn TJ; Khuri FR; Wender RC; Seffrin JR
Colon Cancer Survivorship
Page(s): 307 - 318
01/01/2014 Authors: Kauh J; Khuri FR
Transcriptional regulation of YWHAZ, the gene encoding 14-3-3.
PLoS One Volume: 9 Page(s): e93480
01/01/2014 Authors: Kasinski A; Dong X; Khuri FR; Boss J; Fu H
Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.
PLoS One Volume: 9 Page(s): e107124
01/01/2014 Authors: Brodie SA; Lombardo C; Li G; Kowalski J; Gandhi K; You S; Khuri FR; Marcus A; Vertino PM; Brandes JC
Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Curr Cancer Drug Targets Volume: 14 Page(s): 380 - 393
01/01/2014 Authors: Zhu S; Moore TW; Morii N; Howard RB; Culver D; Arrendale RF; Reddy P; Evers TJ; Zhang H; Sica G
Altered glutamine metabolism and therapeutic opportunities for lung cancer.
Clin Lung Cancer Volume: 15 Page(s): 7 - 15
01/01/2014 Authors: Mohamed A; Deng X; Khuri FR; Owonikoko TK
Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
Cancer Res Volume: 74 Page(s): 212 - 223
01/01/2014 Authors: Xie M; Yen Y; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Doetsch PW; Deng X
The E3 ubiquitin ligases -TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis.
Mol Cancer Volume: 12 Page(s): 146
11/22/2013 Authors: Ren H; Koo J; Guan B; Yue P; Deng X; Chen M; Khuri FR; Sun S-Y
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.
J Clin Oncol Volume: 31 Page(s): 4179 - 4187
11/20/2013 Authors: Karp DD; Lee SJ; Keller SM; Wright GS; Aisner S; Belinsky SA; Johnson DH; Johnston MR; Goodman G; Clamon G
The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis.
J Biol Chem Volume: 288 Page(s): 32528 - 32538
11/08/2013 Authors: Li D; Jin L; Alesi GN; Kim Y-M; Fan J; Seo JH; Wang D; Tucker M; Gu T-L; Lee BH
A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON SMALL CELL LUNG CANCER
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S628 - S629
11/01/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Saba NF; Kono SA; Behera M; Lewis C; Chen Z; Pickens A
TREATMENT WITH THERAPIES MATCHED TO ONCOGENIC DRIVERS IMPROVES SURVIVAL IN PATIENTS WITH LUNG CANCERS: RESULTS FROM THE LUNG CANCER MUTATION CONSORTIUM (LCMC)
Volume: 8 Page(s): S3 - S4
11/01/2013 Authors: Kris MG; Johnson B; Berry L; Kwiatkowski D; Iafrate AJ; Wistuba I; Varella-Garcia M; Franklin W; Aronson S; Su P-F
GALAXY-1: RANDOMIZED PHASE II STUDY OF DOCETAXEL WITH OR WITHOUT GANETESPIB IN ADVANCED LUNG ADENOCARCINOMA: RESULTS IN BIOMARKER SUB-GROUPS AND ALL ADENOCARCINOMA PATIENTS.
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S139 - S139
11/01/2013 Authors: Ramalingam SS; Shapiro G; Hirsh V; Zaric B; Ceric T; Poddubskaya E; Goldman J; Ciuleanu T; Khuri FR; Spicer J
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Mol Cancer Ther Volume: 12 Page(s): 2200 - 2212
10/01/2013 Authors: Li R; Hu Z; Sun S-Y; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
Cancer Lett Volume: 338 Page(s): 229 - 238
09/28/2013 Authors: Ren H; Zhao L; Li Y; Yue P; Deng X; Owonikoko TK; Chen M; Khuri FR; Sun S-Y
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
J Clin Oncol Volume: 31 Page(s): 3320 - 3326
09/20/2013 Authors: Goss GD; O'Callaghan C; Lorimer I; Tsao M-S; Masters GA; Jett J; Edelman MJ; Lilenbaum R; Choy H; Khuri F
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Cancer Res Volume: 73 Page(s): 5485 - 5496
09/01/2013 Authors: Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Energizing the search to target LKB1-mutant tumors.
Cancer Discov Volume: 3 Page(s): 843 - 845
08/01/2013 Authors: Marcus AI; Khuri FR
Paranasal Sinus Squamous Cell Carcinoma Incidence and Survival Based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009
CANCER Volume: 119 Page(s): 2602 - 2610
07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M
Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009.
Cancer Volume: 119 Page(s): 2602 - 2610
07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M
A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors.
Assay Drug Dev Technol Volume: 11 Page(s): 367 - 381
07/01/2013 Authors: Du Y; Fu RW; Lou B; Zhao J; Qui M; Khuri FR; Fu H
Class I HDACs are mediators of smoke-carcinogen induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer
CANCER RESEARCH Volume: 73
07/01/2013 Authors: Brodie SA; Li G; El-Kommos A; Ramalingam SS; Behera M; Kowalski J; Gandhi K; Khuri FH; Vertino P; Brandes JC
Targeting protein-protein interactions as an anticancer strategy.
Trends Pharmacol Sci Volume: 34 Page(s): 393 - 400
07/01/2013 Authors: Ivanov AA; Khuri FR; Fu H
p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms.
Mol Cell Biol Volume: 33 Page(s): 2574 - 2585
07/01/2013 Authors: Jin L; Li D; Lee JS; Elf S; Alesi GN; Fan J; Kang H-B; Wang D; Fu H; Taunton J
Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.
J Gastrointest Cancer Volume: 44 Page(s): 143 - 151
06/01/2013 Authors: Carr JS; Zafar SF; Saba N; Khuri FR; El-Rayes BF
Integration of apoptosis signal-regulating kinase 1-mediated stress signaling with the Akt/protein kinase B-IB kinase cascade.
Mol Cell Biol Volume: 33 Page(s): 2252 - 2259
06/01/2013 Authors: Puckett MC; Goldman EH; Cockrell LM; Huang B; Kasinski AL; Du Y; Wang C-Y; Lin A; Ichijo H; Khuri F
Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
Volume: 31
05/20/2013 Authors: Saba NF; Kono SA; Mendel JR; Hurwitz SJ; Owonikoko TK; Lewis CM; Harvey D; Rogerio JW; Chen Z; Wadsworth T
Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC)
Volume: 31
05/20/2013 Authors: Kris MG; Oxnard GR; Johnson BE; Berry LD; Chen H; Kwiatkowski DJ; Iafrate AJ; Wistuba II; Franklin WA; Aisner D
A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)
Volume: 31
05/20/2013 Authors: Ramalingam SS; Goss GD; Andric ZG; Bondarenko I; Zaric B; Ceric T; Poddubskaya EV; Ciuleanu T-E; Spicer JF; Felip E
A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
Volume: 31
05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK
Integrating patients' values into decisions to enroll in phase I trials: A feasibility study.
Volume: 31
05/20/2013 Authors: Hendershot KA; Dossul T; Wall L; Owonikoko TK; Harvey RD; Thomas CB; McCormick JB; Khuri FR; Pentz RD
Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract
Volume: 31
05/20/2013 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Rossi MR; Adsay V; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z
Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review.
Volume: 31
05/20/2013 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
J Biol Chem Volume: 288 Page(s): 13215 - 13224
05/10/2013 Authors: Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR
Follow-up to expression of concern.
Cancer Volume: 119 Page(s): 1763
05/01/2013 Authors: Khuri FR
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
Cancer Volume: 119 Page(s): 1503 - 1511
04/15/2013 Authors: Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun S-Y; Shin DM; Waller EK; Khuri FR
AICAR induces cell death in LKB1-deficient NSCLC.
Volume: 73
04/15/2013 Authors: Liu F; Zhou W; Liu X; Sun S-Y; Khuri F; He Y-L; Zhong D
Knockdown of death receptor 5 promotes cancer cell invasion through activation of the ERK and JNK signaling pathways.
Volume: 73
04/15/2013 Authors: Oh Y-T; Yue P; Khuri FR; Sun S-Y
Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).
Volume: 73
04/15/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Kono S; Behera M; Mendel J; Chen Z; Pickens A; Fu RW
Rictor undergoes GSK3-dependent, FBXW7-mediated ubiquitination and proteasomal degradation
Volume: 73
04/15/2013 Authors: Koo J; Wu X; Yue P; Mao Z; Khuri FR; Sun S-Y
Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer.
Volume: 73
04/15/2013 Authors: Jiang N; Wang D; Hu Z; Rahman AM; Zhang H; Amin RA; Wang X; Chen Z; Dong SM; Garcia G
Quantification of circulating tumor cells using multiplexed Surface-Enhanced Raman Scattering Nanoparticles.
Volume: 73
04/15/2013 Authors: Wang X; Qian X; Beitler JJ; Chen ZG; Khuri FR; Lewis MM; Shin HJ; Nie S; Shin DM
Development of small molecule BcI-XL inhibitors for treatment of lung cancer
Volume: 73
04/15/2013 Authors: Park D; Magis AT; Li R; Owonikoko TKK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X
p90RSK2 coordinates pro-apoptotic and anti-apoptotic signaling pathways to protect cancer cells from anoikis.
Volume: 73
04/15/2013 Authors: Jin L; Li D; Lee J; Alesi GN; Fan J; Kang H-B; Wang D; Fu H; Taunton J; Boggon TJ
Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC)
Volume: 73
04/15/2013 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri FR; Sun S-Y
Screening of novel small molecule inhibitors of NF-(kappa) B activation in lung cancer
Volume: 27
04/01/2013 Authors: Umstead M; Du Y; Yoo MH; Khuri F; Fu H
Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma.
Cancer Biol Ther Volume: 14 Page(s): 365 - 369
04/01/2013 Authors: Fan S; Mller S; Chen ZG; Pan L; Tighiouart M; Shin DM; Khuri FR; Sun S-Y
Correlates of continued smoking versus cessation among survivors of smoking-related cancers.
Psychooncology Volume: 22 Page(s): 799 - 806
04/01/2013 Authors: Berg CJ; Thomas AN; Mertens AC; Schauer GL; Pinsker EA; Ahluwalia JS; Khuri FR
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Clin Cancer Res Volume: 19 Page(s): 1603 - 1611
03/15/2013 Authors: Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG
mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
Cancer Res Volume: 73 Page(s): 1946 - 1957
03/15/2013 Authors: Zhao L; Yue P; Khuri FR; Sun S-Y
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer Volume: 108 Page(s): 762 - 765
03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
Head Neck Volume: 35 Page(s): 443 - 453
03/01/2013 Authors: Shin DM; Khuri FR
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Lancet Oncol Volume: 14 Page(s): 257 - 264
03/01/2013 Authors: Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ
On collegiality and role models.
Cancer Volume: 119 Page(s): 928 - 930
03/01/2013 Authors: Khuri FR
Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.
Clin Lung Cancer Volume: 14 Page(s): 128 - 138
03/01/2013 Authors: Behera M; Heine JJ; Sica GL; Fowler EE; Tran H; Fu RW; Gal AA; Hermann R; Mayfield W; Khuri FR
Laryngeal tumor volume as a predictor for thyroid cartilage penetration.
Head Neck Volume: 35 Page(s): 426 - 430
03/01/2013 Authors: Kats SS; Muller S; Aiken A; Hudgins PA; Wadsworth JT; Shin DM; Khuri F; Beitler JJ
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Clin Cancer Res Volume: 19 Page(s): 1244 - 1256
03/01/2013 Authors: Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin ARMR; Mller S; Lewis M; Sica G; Kono S
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
J Thorac Oncol Volume: 8 Page(s): 369 - 372
03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
Oncologist Volume: 18 Page(s): 600 - 610
01/01/2013 Authors: Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Am Soc Clin Oncol Educ Book
01/01/2013 Authors: Owonikoko TK; Khuri FR
Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETSTM)" for Cancer Phase I Clinical Trials.
Open Med Inform J Volume: 7 Page(s): 8 - 17
01/01/2013 Authors: Chen Z; Wang Z; Wang H; Owonikoko TK; Kowalski J; Khuri FR
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Oncologist Volume: 18 Page(s): 1262 - 1269
01/01/2013 Authors: Owonikoko TK; Chowdry RP; Chen Z; Kim S; Saba NF; Shin DM; Khuri FR
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
PLoS One Volume: 8 Page(s): e74670
01/01/2013 Authors: Li R; You S; Hu Z; Chen ZG; Sica GL; Khuri FR; Curran WJ; Shin DM; Deng X
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Nat Commun Volume: 4 Page(s): 1790
01/01/2013 Authors: Hitosugi T; Zhou L; Fan J; Elf S; Zhang L; Xie J; Wang Y; Gu T-L; Alekovi M; LeRoy G
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Cancer Lett Volume: 325 Page(s): 139 - 146
12/28/2012 Authors: Ren H; Chen M; Yue P; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
c-Myc suppression of DNA double-strand break repair.
Neoplasia Volume: 14 Page(s): 1190 - 1202
12/01/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Ramalingam SS; Doetsch PW; Xiao Z-Q; Khuri FR; Curran WJ; Deng X
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Cancer Cell Volume: 22 Page(s): 585 - 600
11/13/2012 Authors: Hitosugi T; Zhou L; Elf S; Fan J; Kang H-B; Seo JH; Shan C; Dai Q; Zhang L; Xie J
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.
Cancer Volume: 118 Page(s): 4444 - 4451
09/15/2012 Authors: Ellington CL; Goodman M; Kono SA; Grist W; Wadsworth T; Chen AY; Owonikoko T; Ramalingam S; Shin DM; Khuri FR
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.
Cancer Volume: 118 Page(s): 4571 - 4578
09/15/2012 Authors: Pentz RD; White M; Harvey RD; Farmer ZL; Liu Y; Lewis C; Dashevskaya O; Owonikoko T; Khuri FR
Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease.
Cancer Volume: 118 Page(s): 4370 - 4371
09/15/2012 Authors: Ramalingam SS; Khuri FR
A Systematic Analysis Of High-dose Radiation In The Treatment Of Surgically Unresectable, Locally Advanced Non-small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S212 - S213
09/01/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Deng X; Curran WJ; Khuri FR; Ramalingam SS; Owonikoko TK
Tissue Expression of Activated Phosphorylated Forms of Bcl2 and Mcl1 as Prognostic Markers in Small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S219 - S219
09/01/2012 Authors: Owonikoko TK; Chowdry RP; Chen Z; Goodman A; Kim S; Deng X; Gal A; Khuri FR; Ramalingam SS; Sica G
Parp Enzyme Inhibitor, Veliparib (ABT-888), Potentiates the Efficacy Of Chemotherapy And Radiation In Small Cell Lung Cancer (SCLC)
Volume: 7 Page(s): S278 - S278
09/01/2012 Authors: Owonikoko TK; Zhang G; Deng X; Li C; Beumer JH; Rossi MR; Ramalingam SS; Curran WJ; Sun S; Khuri FR
HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?
Head Neck Pathol Volume: 6 Page(s): 336 - 344
09/01/2012 Authors: Mller S; Khuri FR; Kono SA; Beitler JJ; Shin DM; Saba NF
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
Lung Cancer Volume: 77 Page(s): 331 - 338
08/01/2012 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
Clin Cancer Res Volume: 18 Page(s): 3705 - 3713
07/01/2012 Authors: Hildebrandt MAT; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.
Integr Biol (Camb) Volume: 4 Page(s): 633 - 640
06/01/2012 Authors: Zhu S; Moore TW; Lin X; Morii N; Mancini A; Howard RB; Culver D; Arrendale RF; Reddy P; Evers TJ
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC)
Volume: 30
05/20/2012 Authors: Haddad RI; Rabinowits G; Tishler RB; Adkins D; Khuri FR; Clark J; Lorch JH; Limaye SA; Wirth LJ; O'Neill A
A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer
Volume: 30
05/20/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Kim S; Deng X; Curran WJ; Khuri FR; Ramalingam SS
Using CHFR expression to predict response and survival after first line treatment with carboplatin-paclitaxel in NSCLC.
Volume: 30
05/20/2012 Authors: Pillai RN; Brodie SA; Li G; Herman JG; Brock M; Owonikoko TK; Ramalingam SS; Khuri FR; Brandes JC
Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors.
Volume: 30
05/20/2012 Authors: Chowdry RP; Sica G; Chen Z; Goodman A; Kim S; Deng X; Curran WJ; Gal AA; Khuri FR; Ramalingam SS
Paranasal sinus squamous cell carcinomas (PNSSCC) incidence and survival trends.
Volume: 30
05/20/2012 Authors: Ansa B; Goodman M; Ward K; Kono SA; Kunle T; Grist OW; Wadsworth T; El-Deiry M; Chen AY; Ramalingam SS
Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN)
Volume: 30
05/20/2012 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Eggers C; Phelan VH; Kono SA; Owonikoko TK; Ramalingam SS
A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
Volume: 30
05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF
Physicians' ability to correctly identify values important to cancer patients enrolled in phase I clinical trials.
Volume: 30
05/20/2012 Authors: Pentz RD; Liu Y; Wall L; Daugherty C; Green MJ; Hlubocky FJ; Peterson SK; Sun CC; Dixon M; Harvey RD
Prognostic impact of circulating endothelial cell counts in patients with advanced non-small cell lung cancer
Volume: 30
05/20/2012 Authors: DeJoubner NJ; Kang H; Li Q; Harris WAC; Stewart R; Price A; Quyyumi A; Kono SA; Ramalingam SS; Owonikoko TK
ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.
Volume: 30
05/20/2012 Authors: Varella-Garcia M; Berry LD; Su P-F; Franklin WA; Iafrate AJ; Ladanyi M; Camidge DR; Garon EB; Haura EB; Horn L
Behavior of circulating tumor cells detected by EGF tagged SERS nanoparticles in head and neck cancer patients
Volume: 30
05/20/2012 Authors: Beitler JJ; Wang X; Qian X; Wang H; Chen ZG; Khuri FR; Nie S; Shin DM
NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC/FAK loop.
Cancer Lett Volume: 318 Page(s): 106 - 113
05/01/2012 Authors: Shen J; Xu L; Owonikoko TK; Sun S-Y; Khuri FR; Curran WJ; Deng X
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.
J Thorac Oncol Volume: 7 Page(s): 866 - 872
05/01/2012 Authors: Owonikoko TK; Behera M; Chen Z; Bhimani C; Curran WJ; Khuri FR; Ramalingam SS
Synergistic apoptosis by combination of natural compound EGCG and resveratrol in head and neck cancer: Potential role for AKT-dependent signaling
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Amin ARMR; Rahman MA; Wang D; Khuri FR; Chen ZG; Shin DM
Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Zhang H; Hu Z; Phelan V; Liu Y; Muller S; Saba NF; Beitler JJ; Khuri FR; Chen GZ; Shin DM
c-Myc suppresses DNA double-strand break repair
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Xiao Z-Q; Doetsch PW; Khuri FR; Curran WJ; Deng X
GSK3 plays a crucial role in determining cell response to mTOR inhibitors
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Koo J; Yue P; Tao H; Ramalingam SS; Khuri FR; Sun S-Y
An endogenous mTOR inhibitor, PRAS40, is upregulated in lung cancer and contributes to tumor cell invasion and chemoresistance
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Li Z; Du Y; Sica G; Ramalingam SS; Gal AA; Pan L; Tighiouart MM; Khuri FRFR; Fu H
The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Li B; Rentsch H; Yue P; Chen M; Khuri FR; Sun S
mTOR complex 2 is involved in regulation of c-FLIP stability and sensitization of TRAIL-induced apoptosis
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Zhao L; Yue P; Khuri FR; Sun S-Y
SUMOylation of EAPII/TTRAP/TDP2 modulates its function
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Li C; Khuri FR; Sun S-Y; Li R
The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.
Cancer Prev Res (Phila) Volume: 5 Page(s): 612 - 620
04/01/2012 Authors: Li B; Ren H; Yue P; Chen M; Khuri FR; Sun S-Y
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Cancer Biol Ther Volume: 13 Page(s): 272 - 280
03/01/2012 Authors: Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
Expression of concern.
Cancer Volume: 118 Page(s): 1173
02/15/2012 Authors: Khuri FR; Pollock RE
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
J Biol Chem Volume: 287 Page(s): 257 - 267
01/02/2012 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.
Mol Cancer Ther Volume: 11 Page(s): 45 - 56
01/01/2012 Authors: Liu Y; Sun S-Y; Owonikoko TK; Sica GL; Curran WJ; Khuri FR; Deng X
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.
Cancer Volume: 118 Page(s): 164 - 172
01/01/2012 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JR; Saba NR; Shin DM; Curran WJ; Khuri FR
Research biopsies in phase I studies: views and perspectives of participants and investigators.
IRB Volume: 34 Page(s): 1 - 8
01/01/2012 Authors: Pentz RD; Harvey RD; White M; Farmer ZL; Dashevskaya O; Chen Z; Lewis C; Owonikoko TK; Khuri FR
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.
Mol Cell Volume: 44 Page(s): 864 - 877
12/23/2011 Authors: Hitosugi T; Fan J; Chung T-W; Lythgoe K; Wang X; Xie J; Ge Q; Gu T-L; Polakiewicz RD; Roesel JL
Why Cancer matters.
Cancer Volume: 117 Page(s): 5436 - 5438
12/15/2011 Authors: Khuri FR
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.
Mol Cell Biol Volume: 31 Page(s): 4938 - 4950
12/01/2011 Authors: Fan J; Hitosugi T; Chung T-W; Xie J; Ge Q; Gu T-L; Polakiewicz RD; Chen GZ; Boggon TJ; Lonial S
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
Mol Cancer Ther Volume: 10 Page(s): 2415 - 2425
12/01/2011 Authors: Zhao L; Yue P; Lonial S; Khuri FR; Sun S-Y
Patterns of extralaryngeal spread of laryngeal cancer: thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers.
Cancer Volume: 117 Page(s): 5047 - 5051
11/15/2011 Authors: Chen SA; Muller S; Chen AY; Hudgins PA; Shin DM; Khuri F; Saba NF; Beitler JJ
Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data.
Biomed Eng Online Volume: 10 Page(s): 97
11/08/2011 Authors: Behera M; Fowler EE; Owonikoko TK; Land WH; Mayfield W; Chen Z; Khuri FR; Ramalingam SS; Heine JJ
Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond.
Cell Cycle Volume: 10 Page(s): 3274 - 3283
10/01/2011 Authors: Li C; Sun S-Y; Khuri FR; Li R
Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.
Cancer Res Volume: 71 Page(s): 6270 - 6281
10/01/2011 Authors: Chen S; Cao W; Yue P; Hao C; Khuri FR; Sun S-Y
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.
Proc Natl Acad Sci U S A Volume: 108 Page(s): 16212 - 16216
09/27/2011 Authors: Zhao J; Du Y; Horton JR; Upadhyay AK; Lou B; Bai Y; Zhang X; Du L; Li M; Wang B
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
Cancer Biol Ther Volume: 12 Page(s): 549 - 555
09/15/2011 Authors: Xu C-X; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
14-3-3 proteins as potential therapeutic targets.
Semin Cell Dev Biol Volume: 22 Page(s): 705 - 712
09/01/2011 Authors: Zhao J; Meyerkord CL; Du Y; Khuri FR; Fu H
A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
Volume: 47 Page(s): S153 - S153
09/01/2011 Authors: Harvey RD; Lewis CM; Kauh JS; Owonikoko TK; Akintayo A; Karol M; Teofilovici F; Lufkin JM; Khuri FR; Ramalingam SS
Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.
Oncogene Volume: 30 Page(s): 3802 - 3812
09/01/2011 Authors: Li C; Fan S; Owonikoko TK; Khuri FR; Sun S-Y; Li R
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Cancer Volume: 117 Page(s): 4049 - 4059
09/01/2011 Authors: Kauh J; Chanel-Vos C; Escuin D; Fanucchi MP; Harvey RD; Saba N; Shin DM; Gal A; Pan L; Kutner M
Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.
Cancer Res Volume: 71 Page(s): 5245 - 5254
08/01/2011 Authors: Dhandapani L; Yue P; Ramalingam SS; Khuri FR; Sun S-Y
The dawn of a revolution in personalized lung cancer prevention.
Cancer Prev Res (Phila) Volume: 4 Page(s): 949 - 953
07/01/2011 Authors: Khuri FR
MOLECULAR MECHANISMS OF CHEMOPREVENTIVE COMPOUNDS AND NOVEL APPROACHES (MOLECULAR IMAGING) TO ASSESS EFFICACY
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S115 - S116
06/01/2011 Authors: Khuri FR; Sun S-Y; Brandes JC; Fu H
CLINICAL CHARACTERISTICS OF PLANNED 1000 PATIENTS WITH ADENOCARCINOMA OF LUNG (ACL) UNDERGOING GENOMIC CHARACTERIZATION IN THE US LUNG CANCER MUTATION CONSORTIUM (LCMC)
Volume: 6 Page(s): S344 - S345
06/01/2011 Authors: Johnson BE; Kris MG; Kwiatkowski D; Iafrate AJ; Wistuba II; Shyr Y; Engelman J; Khuri FR; Dubinett S; Pao W
The BATTLE trial: personalizing therapy for lung cancer.
Cancer Discov Volume: 1 Page(s): 44 - 53
06/01/2011 Authors: Kim ES; Herbst RS; Wistuba II; Lee JJ; Blumenschein GR; Tsao A; Stewart DJ; Hicks ME; Erasmus J; Gupta S
A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S967 - S968
06/01/2011 Authors: Owonikoko TK; Force S; Sica G; Bechara R; Harvey RD; Sun S-Y; Saba N; Rogerio J; Gal A; Kono S
ANALYSIS OF MTOR SIGNALING PATHWAY BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH EVEROLIMUS AND DOCETAXEL IN A PHASE II CLINICAL TRIAL.
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1039 - S1040
06/01/2011 Authors: Owonikoko TK; Ramalingam S; Subramanian J; Sica G; Chen Z; Behera M; Rogerio J; Saba N; Tighiouart M; Gal A
ROLE OF HDAC INHIBITION IN THE REVERSAL OF EPIGENETIC GENE SILENCING IN LUNG CARCINOGENESIS.
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S677 - S677
06/01/2011 Authors: Brodie SA; El-Kommos A; Ramalingam S; Khuri FR; Brandes JC
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
J Clin Oncol Volume: 29 Page(s): e13601
05/20/2011 Authors: Khuri FR; Owonikoko TK; Subramanian J; Sica G; Behera M; Saba NF; Chen Z; Tighiouart M; Shin DM; Sun S
Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
J Clin Oncol Volume: 29 Page(s): 7602
05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
J Clin Oncol Volume: 29 Page(s): 7553
05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
J Clin Oncol Volume: 29 Page(s): 5585
05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
J Clin Oncol Volume: 29 Page(s): e14569
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS
Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Chowdry RP; Bhimani C; Ramalingam SS; Khuri FR; Owonikoko TK
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
Volume: 29
05/20/2011 Authors: Kris MG; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Wistuba II; Aronson SL; Engelman JA; Shyr Y; Khuri FR; Rudin CM
Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK
Tyrosine phosphorylation of LDH-A is important for cancer cell redox homeostasis and tumor growth
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Fan J; Hitosugi T; Chung T-W; Wang X; Gu T-L; Roesel JL; Chen ZG; Boggon T; Khuri FR; Kang S
Tyrosine phosphorylation of LDH-A is important for cancer cell redox homeostasis and tumor growth
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Fan J; Hitosugi T; Chung T-W; Wang X; Gu T-L; Roesel JL; Chen ZG; Boggon T; Khuri FR; Kang S
Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK
NNK promotes migration and invasion of cancer cells through activation of c-Src, PKCI and FAK loop
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Shen J; Xu L; Sun S-Y; Khuri F; Deng X
RSK2 phosphorylates and activates CREB to promote HNSCC cell invasion through upregulation of pro-metastatic MCAM and Fascin-1
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Jin L; Kim Y-M; Zhou W; Taunton J; Chen GZ; Shin DM; Khuri FR; Kang S
Inhibition of head and neck squamous cell carcinoma growth by combination treatment of erlotinib and celecoxib: Potential chemopreventive agents
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Zhang H; Nannapaneni S; Chen Z; Saba N; Khuri FR; Chen GZ; Shin DM
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through JNK-dependent downregulation of c-FLIP in head and neck cancer cells
Volume: 71
04/15/2011 Authors: Zhao L; Yue P; Lonial S; Khuri FR; Sun S-Y
The Cables1 protein complex couples survival signaling to cell death machinery
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Shi Z; Park HR; Du Y; Fu H; Khuri FR
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Chung T-W; Hitosugi T; Fan J; Wang X; Gu T-L; Roesei JL; Boggon T; Chen ZG; Khuri FR; Kang S
Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC)
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri F; Sun S-Y
LKB1 negatively regulates IGF-1 induced ERK phosphorylation
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Zhong D; Liu X; Fu H; Sun S-Y; Khuri FR; Zhou W
Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK
Elevated eukaryotic translation initiation factor 4E (eIF4E) is involved in erlotinib resistance
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Li Y; Koo J; Fan S; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
Oncogenic role of EAPII/TTRAP in lung cancer development and its activation of MAPK-ERK pathway
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Li C; Fan S; Owonikoko TK; Khuri FR; Sun S-Y; Li R
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles.
Cancer Res Volume: 71 Page(s): 1526 - 1532
03/01/2011 Authors: Wang X; Qian X; Beitler JJ; Chen ZG; Khuri FR; Lewis MM; Shin HJC; Nie S; Shin DM
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.
Cancer Prev Res (Phila) Volume: 4 Page(s): 185 - 193
02/01/2011 Authors: Lee JJ; Wu X; Hildebrandt MAT; Yang H; Khuri FR; Kim E; Gu J; Ye Y; Lotan R; Spitz MR
Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
Oncology Volume: 81 Page(s): 12 - 20
01/01/2011 Authors: Saba NF; Goodman M; Ward K; Flowers C; Ramalingam S; Owonikoko T; Chen A; Grist W; Wadsworth T; Beitler JJ
Lung cancer: New biological insights and recent therapeutic advances.
CA Cancer J Clin Volume: 61 Page(s): 91 - 112
01/01/2011 Authors: Ramalingam SS; Owonikoko TK; Khuri FR
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
PLoS One Volume: 6 Page(s): e20899
01/01/2011 Authors: Xu C-X; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
J Biol Chem Volume: 285 Page(s): 41310 - 41319
12/31/2010 Authors: Oh Y-T; Liu X; Yue P; Kang S; Chen J; Taunton J; Khuri FR; Sun S-Y
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Mol Cancer Volume: 9 Page(s): 315
12/20/2010 Authors: Fu L; Lin Y-D; Elrod HA; Yue P; Oh Y; Li B; Tao H; Chen GZ; Shin DM; Khuri FR
Results of a Phase II Study of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-small Cell Lung Cancer by Japan Clinical Oncology Group (JCOG0403)
Volume: 5 Page(s): S502 - S503
12/01/2010 Authors: Hiraoka M; Nagata Y; Shibata T; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Kunieda E; Ishikura S
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Carcinogenesis Volume: 31 Page(s): 2118 - 2123
12/01/2010 Authors: Zhang X; Yang H; Lee JJ; Kim E; Lippman SM; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth
Volume: 116 Page(s): 1294 - 1294
11/19/2010 Authors: Hitosugi T; Kang S; Vander Heiden M; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen G
Lung cancer in the elderly: what's age got to do with it?
Oncology (Williston Park) Volume: 24 Page(s): 1120 - 1129
11/15/2010 Authors: Owonikoko TK; Ramalingam SS; Khuri FR
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53.
J Biol Chem Volume: 285 Page(s): 34557 - 34565
11/05/2010 Authors: Amin ARMR; Wang D; Zhang H; Peng S; Shin HJC; Brandes JC; Tighiouart M; Khuri FR; Chen ZG; Shin DM
Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
Biochem Pharmacol Volume: 80 Page(s): 1309 - 1316
11/01/2010 Authors: Thomas SL; Zhao J; Li Z; Lou B; Du Y; Purcell J; Snyder JP; Khuri FR; Liotta D; Fu H
Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax.
PLoS One Volume: 5 Page(s): e13393
10/14/2010 Authors: Wang Q; Sun S-Y; Khuri F; Curran WJ; Deng X
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Neoplasia Volume: 12 Page(s): 848 - 855
10/01/2010 Authors: Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun S-Y
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.
Carcinogenesis Volume: 31 Page(s): 1755 - 1761
10/01/2010 Authors: Wang J; Lippman SM; Lee JJ; Yang H; Khuri FR; Kim E; Lin J; Chang DW; Lotan R; Hong WK
caGrid-Enabled caBIG Silver Level Compatible Head and Neck Cancer Tissue Database System.
Open Med Inform J Volume: 4 Page(s): 171 - 178
09/01/2010 Authors: Wang H; Bouzyk E; Kuehn A; Muller S; Chen Z; Khuri FR; Shin DM; Rogatko A; Tighiouart M
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.
PLoS One Volume: 5 Page(s): e12178
08/16/2010 Authors: Elrod HA; Fan S; Muller S; Chen GZ; Pan L; Tighiouart M; Shin DM; Khuri FR; Sun S-Y
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Cancer Volume: 116 Page(s): 3903 - 3909
08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
Ther Adv Med Oncol Volume: 2 Page(s): 229 - 235
07/01/2010 Authors: Jiang Y; Owonikoko TK; Ramalingam SS; Khuri FR; Belani CP
Cancer prevention with natural compounds.
Semin Oncol Volume: 37 Page(s): 258 - 281
06/01/2010 Authors: Gullett NP; Ruhul Amin ARM; Bayraktar S; Pezzuto JM; Shin DM; Khuri FR; Aggarwal BB; Surh Y-J; Kucuk O
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
J Biol Chem Volume: 285 Page(s): 16096 - 16104
05/21/2010 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y
Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Saba NF; Muller S; Chen AY; Grist W; Gibson K; Nannapaneni S; Yang CS; Khuri FR; Chen ZG; Shin DM
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR
Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Owonikoko TK; Ramalingam SS; Behera M; Brandes JC; Saba NF; Bhimani C; Harichand-Herdt S; Shin DM; Khuri FR; Ragin C
Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Harvey RD; Kauh JS; Ramalingam SS; Lewis CM; Chen Z; Lonial S; Blount IC; Shin DM; Khuri FR; Owanikoko TK
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report
Volume: 28
05/20/2010 Authors: Haddad RI; Tishler RB; Adkins D; Khuri FR; Clark J; Lorch JH; Wirth LJ; Sarlis NJ; Jaffa Z; Posner MR
PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)
Volume: 28
05/20/2010 Authors: Campbell A; Reckamp KL; Camidge DR; Giaccone G; Gadgeel SM; Khuri FR; Engelman JA; Denis LJ; O'Connell JP; Janne PA
HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JC; Saba NF; Curran WJ; Khuri FR; Ramalingam SS
THE BIOLOGICAL SIGNIFICANCE OF TARGETED THERAPIES: THE DEVELOPMENT OF MTOR INHIBITORS
JOURNAL OF THORACIC ONCOLOGY Volume: 5 Page(s): S27 - S27
05/01/2010 Authors: Khuri FR; Ramalingam SS; Owonikoko TK; Sun S-Y; Fu H
MOLECULAR EXPRESSION OF ANGIOGENIC MARKERS IN EARLY-STAGE NSCLC: EVALUATION OF THE PROGNOSTIC ROLE
Volume: 5 Page(s): S67 - S67
05/01/2010 Authors: Jantus E; Cabrera A; Sirera R; Uso M; Gallach S; Blasco A; Berrocal A; Taron M; Rosell R; Camps C
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
PLoS One Volume: 5 Page(s): e10376
04/28/2010 Authors: Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun S-Y
Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines
CANCER RESEARCH Volume: 70
04/01/2010 Authors: Owonikoko TK; Zhang G; Ramalingam SS; Khuri FR; Sun S-Y
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
Am J Clin Oncol Volume: 33 Page(s): 148 - 152
04/01/2010 Authors: William WN; Khuri FR; Fossella FV; Glisson BS; Zinner RG; Lee JJ; Herbst RS; Lippman SM; Kim ES
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.
J Clin Invest Volume: 120 Page(s): 1165 - 1177
04/01/2010 Authors: Kang S; Elf S; Lythgoe K; Hitosugi T; Taunton J; Zhou W; Xiong L; Wang D; Muller S; Fan S
Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax
Volume: 70
04/01/2010 Authors: Wang Q; Wang T; Gao F; Sun S-Y; Khuri FR; Curran WJ; Deng X
Cytoplasmic location of CXCR4 is correlated to loss of EMT marker and activation of downstream signaling pathway in non-small cell lung cancer
Volume: 70
04/01/2010 Authors: Wang Y; Huang D; Fu H; Wang D; Koenig L; Khuri FR; Shin DM; Chen ZG
Acetylated tubulin (AT) levels predicts response to TPF chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC)
CANCER RESEARCH Volume: 70
04/01/2010 Authors: Saba NF; Marcus A; Beitler JJ; Muller S; Eggers C; Grist W; Chen A; Chen Z; Shin DM; Khuri FR
Retinoic acid regulates TRAIL-R1 expression through a retinoic acid receptor-dependent mechanism and enhances death receptor-induced apoptosis
Volume: 70
04/01/2010 Authors: Dhandapani L; Yue P; Ramalingam SS; Khuri FR; Sun SY
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Neoplasia Volume: 12 Page(s): 346 - 356
04/01/2010 Authors: Fan S; Li Y; Yue P; Khuri FR; Sun S-Y
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact
Volume: 70
04/01/2010 Authors: Elrod HA; Fan S; Muller S; Chen GZ; Pan L; Tighiouart M; Shin DM; Khuri FR; Sun S-Y
Inhibition of ASK1 through phosphorylation of serine 967 by PI3K/Akt-mediated pathways
Volume: 70
04/01/2010 Authors: Puckett MC; Goldman E; Cockrell L; Khuri F; Fu H
The histone deacetylase inhibitor LBH589 sensitizes pancreatic cancer cells to TRAIL-induced apoptosis through induction of c-FLIP degradation
Volume: 70
04/01/2010 Authors: Kauh J; Fan S; Yang L; Khuri FR; Sun S-Y
Oncogenic tyrosine kinases phosphorylate and inhibit PKM2 to provide a metabolic advantage to tumor growth
Volume: 70
04/01/2010 Authors: Hitosugi T; Kang S; Heiden MGV; Chung T-W; Lonial S; Wang X; Chen GZ; Xie J; Gu T-L; Polakiewicz RD
Through the Looking Glass: The Evolution of Erythropoiesis-Stimulating Agent Use The Bennett/McKoy/Henke et al article reviewed
ONCOLOGY-NEW YORK Volume: 24 Page(s): 269 - 274
03/01/2010 Authors: Harvey RD; Khuri FR; Kauh JS
Through the looking glass: the evolution of erythropoiesis-stimulating agent use.
Oncology (Williston Park) Volume: 24 Page(s): 269 - 274
03/01/2010 Authors: Harvey RD; Khuri FR; Kauh JS
Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome.
Oncogene Volume: 29 Page(s): 822 - 830
02/11/2010 Authors: Cockrell LM; Puckett MC; Goldman EH; Khuri FR; Fu H
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
Mol Cancer Volume: 9 Page(s): 23
01/29/2010 Authors: Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun S-Y
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
Cancer Res Volume: 69 Page(s): 8967 - 8976
12/01/2009 Authors: Fu L; Kim Y-A; Wang X; Wu X; Yue P; Lonial S; Khuri FR; Sun S-Y
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Sci Signal Volume: 2 Page(s): ra73
11/17/2009 Authors: Hitosugi T; Kang S; Vander Heiden MG; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen GZ
Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis.
Head Neck Volume: 31 Page(s): 1447 - 1455
11/01/2009 Authors: Saba NF; Edelman S; Tighiouart M; Gaultney J; Davis LW; Khuri FR; Chen A; Grist W; Shin DM
PI3 Kinase, mTOR, and AKT Pathways
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S1059 - S1060
11/01/2009 Authors: Ramalingam SS; Khuri FR
PI3 kinase, mTOR, and AKT pathways.
J Thorac Oncol Volume: 4 Page(s): S1059 - S1060
11/01/2009 Authors: Ramalingam SS; Khuri FR
Preoperative therapy for early-stage NSCLC: opportunities and challenges.
Oncology (Williston Park) Volume: 23 Page(s): 886 - 892
09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS
Targeting the IGF-1R in lung cancer prevention and therapy
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S189 - S190
09/01/2009 Authors: Owonikoko TK; Ramalingam S; Sun S-Y; Khuri FR
Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Volume: 7 Page(s): 558 - 559
09/01/2009 Authors: Soria JC; Bennouna J; Leighl N; Khuri F; Traynor AM; Johnson B; Kay A; Blais N; Jehl V; Papadimitrakopoulou V
Induction trial of RAD001 in operable lung cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S43 - S44
09/01/2009 Authors: Khuri FR; Ramalingam S; Fu H; Sun S-Y
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Mol Cancer Ther Volume: 8 Page(s): 2575 - 2585
09/01/2009 Authors: Elrod HA; Yue P; Khuri FR; Sun S-Y
A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results
Volume: 4 Page(s): S293 - S294
09/01/2009 Authors: Janne PA; Reckamp K; Koczywas M; Camidge DR; Engelman JA; Khuri F; Rajan A; Gadgeel S; Taylor I; Liang J
Phase 2 study of ABT-869 in combination with Carboplatin/Paclitaxel (CP) in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC): lead-in cohort results
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S706 - S706
09/01/2009 Authors: Ramalingam S; Owonikoko T; Khuri F; Saba N; Wallace J; Qian J; Gupta N; Ricker J; Carlson D
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challenges OWONIKOKO Article Reviewed
ONCOLOGY-NEW YORK Volume: 23 Page(s): 886 - 892
09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Cancer Prev Res (Phila) Volume: 2 Page(s): 823 - 829
09/01/2009 Authors: Saba NF; Choi M; Muller S; Shin HJC; Tighiouart M; Papadimitrakopoulou VA; El-Naggar AK; Khuri FR; Chen ZG; Shin DM
A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S594 - S595
09/01/2009 Authors: Owonikoko TK; Ramalingam SS; Harvey D; Saba NF; Kauh J; Shin DM; Sun S-Y; Browning K; Tighiouart M; Khuri FR
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R.
J Biol Chem Volume: 284 Page(s): 23225 - 23233
08/28/2009 Authors: Zhong D; Xiong L; Liu T; Liu X; Liu X; Chen J; Sun S-Y; Khuri FR; Zong Y; Zhou Q
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.
Cancer Biol Ther Volume: 8 Page(s): 1463 - 1469
08/01/2009 Authors: Fan S; Ramalingam SS; Kauh J; Xu Z; Khuri FR; Sun S-Y
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants.
Cancer Prev Res (Phila) Volume: 2 Page(s): 617 - 624
07/01/2009 Authors: Wu X; Spitz MR; Lee JJ; Lippman SM; Ye Y; Yang H; Khuri FR; Kim E; Gu J; Lotan R
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Nanotechnology Volume: 20 Page(s): 225102
06/03/2009 Authors: Huang D-H; Su L; Peng X-H; Zhang H; Khuri FR; Shin DM; Chen ZG
Perspectives for cancer prevention with natural compounds.
J Clin Oncol Volume: 27 Page(s): 2712 - 2725
06/01/2009 Authors: Amin ARMR; Kucuk O; Khuri FR; Shin DM
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Cancer Prev Res (Phila) Volume: 2 Page(s): 538 - 545
06/01/2009 Authors: Amin ARMR; Khuri FR; Chen ZG; Shin DM
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
Am J Clin Oncol Volume: 32 Page(s): 274 - 279
06/01/2009 Authors: Hanrahan EO; Kies MS; Glisson BS; Khuri FR; Feng L; Tran HT; Ginsberg LE; Truong MT; Hong WK; Kim ES
Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial
Volume: 27
05/20/2009 Authors: Janne PA; Reckamp K; Koczywas M; Engelman JA; Camidge DR; Rajan A; Khuri F; Liang JQ; O'Connell J; Giaccone G
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial
Volume: 27
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
Volume: 27
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
J Clin Oncol Volume: 27 Page(s): 8060
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial.
J Clin Oncol Volume: 27 Page(s): 2512
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD
Effect of the protein Farnesyltransferase expression on HDAC6 activity and cellular sensitivity to taxane treatment
Volume: 69
05/01/2009 Authors: Chanel-Vos C; Gjyrezi A; Kauh J; Khuri F; Giannakakou P
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-induced apoptosis through DR5 induction and c-FLIP downregulation independent of inhibition of cap-dependent protein translation
Volume: 69
05/01/2009 Authors: Fan S; Li Y; Yue P; Khuri F; Sun S-Y
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E (eIF4E) phosphorylation and eIF4F activity
Volume: 69
05/01/2009 Authors: Li Y; Wang X; Khuri F; Sun S-Y
Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents.
Curr Opin Oncol Volume: 21 Page(s): 232 - 237
05/01/2009 Authors: Saba NF; Khuri FR
Anticancer activity profiling of a panel of curcumin analogues in head and neck and lung cancer cells
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Lou B; Du Y; Kasinski A; Thomas S; Sun A; Sun S-Y; Chen G; Shin D; Khuri F; Liotta D
Web-based head and neck cancer tissue database
Volume: 69
05/01/2009 Authors: Wang H; Kuehn A; Bouzyk E; Muller S; Khuri F; Shin D; Tighiouart M
Erlotinib enhances RAD001\#8217;s anticancer activity in vivo involving abrogation of mTOR inhibition-induced eIF4E phosphorylation
Volume: 69
05/01/2009 Authors: Fan S; Wang X; Yue P; Kauh J; Ramalingam S; Khuri F; Sun S-Y
Differential roles of DR4, DR5 and c-FLIP in regulation of geranylgeranyltransferase I inhibitor-induced augmentation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Volume: 69
05/01/2009 Authors: Chen S; Fu L; Raja SM; Yue P; Peterson YK; Khuri FR; Sun S-Y
Regulation of the tumor suppressor Cables1 by Akt/PKB-induced 14-3-3 interaction
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Shi Z; Park HR; Li Z; Ho C; Khuri F; Fu H
Regulation of the tumor suppressor Cablesl by Akt/PKB-induced 14-3-3 interaction
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Shi Z; Park HR; Li Z; Ho C; Khuri F; Fu H
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by Erlotinib and EGCG: the role of p53-dependent inhibition of nuclear factor-\#922;B
Volume: 69
05/01/2009 Authors: Amin ARM; Zhang X; Khuri F; Chen Z; Shin D
In vitro and in vivo synergistic anti-tumor efficacy of two naturally available dietary polyphenols EGCG and luteolin
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Amin A; Wang D; Khuri F; Chen Z; Shin D
Development of a quantum dots (QDs)-based quantification method for multiplexed biomarkers in prediction of metastasis
Volume: 69
05/01/2009 Authors: Huang D-H; Hoyt C; Peng X-H; Wang D; Zhang H; Khuri F; Shin D; Chen Z
Anticancer activity profiling of a panel of curcumin analogues in head and neck and lung cancer cells
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Iou B; Du Y; Kasinski A; Thomas S; Sun A; Sun S-Y; Chen G; Shin D; Khuri F; Liotta D
In vitro and in vivo synergistic anti-tumor efficacy of two naturally available dietary polyphenols EGCG and luteolin
Volume: 69
05/01/2009 Authors: Amin A; Wang D; Khuri F; Chen Z; Shin D
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
J Clin Oncol Volume: 27 Page(s): 1976 - 1982
04/20/2009 Authors: Holsinger FC; Kies MS; Diaz EM; Gillenwater AM; Lewin JS; Ginsberg LE; Glisson BS; Garden AS; Ark N; Lin HY
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
J Biol Chem Volume: 284 Page(s): 9648 - 9655
04/10/2009 Authors: Zhou J; Vos CC; Gjyrezi A; Yoshida M; Khuri FR; Tamanoi F; Giannakakou P
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
Oncologist Volume: 14 Page(s): 412 - 424
04/01/2009 Authors: Ramalingam SS; Khuri FR
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
J Clin Oncol Volume: 27 Page(s): 599 - 604
02/01/2009 Authors: Papadimitrakopoulou VA; Lee JJ; William WN; Martin JW; Thomas M; Kim ES; Khuri FR; Shin DM; Feng L; Hong WK
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
Am J Clin Oncol Volume: 32 Page(s): 15 - 19
02/01/2009 Authors: William WN; Lee JL; Shin DM; Hong WK; Liu S; Lee JJ; Lippman SM; Khuri FR; Kim ES
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
J Recept Signal Transduct Res Volume: 29 Page(s): 182 - 194
01/01/2009 Authors: Du Y; Li Z; Li L; Chen ZG; Sun S-Y; Chen P; Shin DM; Khuri FR; Fu H
SLEEP DISORDERED BREATHING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Volume: 32 Page(s): A340 - A340
01/01/2009 Authors: Vena C; Bechara R; Khuri F; Parker K
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Cancer Biol Ther Volume: 7 Page(s): 1952 - 1958
12/01/2008 Authors: Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun S-Y
A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptides.
Curr Chem Genomics Volume: 2 Page(s): 40 - 47
11/06/2008 Authors: Du Y; Khuri FR; Fu H
Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
Mol Cancer Ther Volume: 7 Page(s): 3556 - 3565
11/01/2008 Authors: Lin Y; Liu X; Yue P; Benbrook DM; Berlin KD; Khuri FR; Sun S-Y
Effective combination of green tea EGCG and EGFR-TKI erlotinib for chemoprevention and therapy in head and neck cancer
Volume: 6 Page(s): 38 - 38
10/01/2008 Authors: Shin DM; Amin ARM; Zhang X; Chen ZG; Khuri FR
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
Cancer Res Volume: 68 Page(s): 7409 - 7418
09/15/2008 Authors: Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun S-Y
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.
Cancer Res Volume: 68 Page(s): 7484 - 7492
09/15/2008 Authors: Zou W; Yue P; Khuri FR; Sun S-Y
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins.
Cancer Res Volume: 68 Page(s): 7270 - 7277
09/15/2008 Authors: Zhong D; Liu X; Khuri FR; Sun S-Y; Vertino PM; Zhou W
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Int J Cancer Volume: 123 Page(s): 1005 - 1014
09/01/2008 Authors: Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'G'; Shin DM
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.
Mol Pharmacol Volume: 74 Page(s): 654 - 661
09/01/2008 Authors: Kasinski AL; Du Y; Thomas SL; Zhao J; Sun S-Y; Khuri FR; Wang C-Y; Shoji M; Sun A; Snyder JP
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.
Mol Cancer Ther Volume: 7 Page(s): 2212 - 2223
07/01/2008 Authors: Raja SM; Chen S; Yue P; Acker TM; Lefkove B; Arbiser JL; Khuri FR; Sun S-Y
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Cancer Res Volume: 68 Page(s): 5335 - 5344
07/01/2008 Authors: Lin Y-D; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun S-Y
From nihilism to individualism: the evolution of lung cancer therapy.
Am J Respir Crit Care Med Volume: 177 Page(s): 1299 - 1300
06/15/2008 Authors: Khuri FR; Roman J
Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion.
Cancer Res Volume: 68 Page(s): 4013 - 4017
06/01/2008 Authors: May KA; Khuri FR
Research participants' views of nontherapeutic biopsies
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Pentz RD; Xu Z; Lonial S; Kauh JS; O'Regan RM; Waller EK; Shin DM; Fu H; Khuri F
Laryngeal squamous cell carcinoma metastatic to a flank intramuscular lipoma.
Am Surg Volume: 74 Page(s): 447 - 448
05/01/2008 Authors: Momin TA; Deyrup AT; Grist WJ; Khuri FR; Kooby DA
Defining the interaction of docetaxel and lonafarnib in patients with advanced malignancies
Volume: 68
05/01/2008 Authors: Kauh J; Fanucchi M; Escuin D; Saba N; Shin D; Gal A; Kutner M; Harvey D; Giannakakou P; Khuri F
Inhibition of Erlotinib-induced checkpoint but not apoptotic targets by EGCG: Implication for their anti-tumor synergism in squamous cell carcinoma of the head and neck
Volume: 68
05/01/2008 Authors: Amin ARM; Zhang X; Khuri F; Chen Z; Shin D
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Volume: 26 Page(s): 1879 - 1885
04/10/2008 Authors: Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun S-L; Zhang JK; Dziewanowska ZE
Synergistic Anticancer Potential of the Combination of the Novel Curcumin Analog EF24 and p38 MAPK Inhibitors
FASEB JOURNAL Volume: 22
04/01/2008 Authors: Thomas S; Khuri F; Snyder J; Liotta D; Fu H
Role of 14-3-3zeta in Anoikis Resistance and Anchorage-independent Growth of Lung Cancer Cells
FASEB JOURNAL Volume: 22
04/01/2008 Authors: Zhao J; Li Z; Du Y; Park HR; Sun S-Y; Khuri F; Fu H
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition.
Mol Cancer Ther Volume: 7 Page(s): 809 - 817
04/01/2008 Authors: Zhong D; Liu X; Schafer-Hales K; Marcus AI; Khuri FR; Sun S-Y; Zhou W
Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Clin Cancer Res Volume: 14 Page(s): 1581 - 1589
03/01/2008 Authors: Oh SH; Jin Q; Kim ES; Khuri FR; Lee H-Y
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity.
Cancer Res Volume: 68 Page(s): 740 - 748
02/01/2008 Authors: Zhang S; Schafer-Hales K; Khuri FR; Zhou W; Vertino PM; Marcus AI
Head and neck cancer chemoprevention gets a shot in the arm.
J Clin Oncol Volume: 26 Page(s): 345 - 347
01/20/2008 Authors: Khuri FR; Shin DM
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation.
Proc Natl Acad Sci U S A Volume: 105 Page(s): 162 - 167
01/08/2008 Authors: Li Z; Zhao J; Du Y; Park HR; Sun S-Y; Bernal-Mizrachi L; Aitken A; Khuri FR; Fu H
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.
J Natl Cancer Inst Volume: 99 Page(s): 1603 - 1612
11/07/2007 Authors: Hittelman WN; Liu DD; Kurie JM; Lotan R; Lee JS; Khuri F; Ibarguen H; Morice RC; Walsh G; Roth JA
Translation of innovative designs into phase I trials.
J Clin Oncol Volume: 25 Page(s): 4982 - 4986
11/01/2007 Authors: Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Mol Pharmacol Volume: 72 Page(s): 1269 - 1279
11/01/2007 Authors: Chen S; Liu X; Yue P; Schnthal AH; Khuri FR; Sun S-Y
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Mol Cell Biol Volume: 27 Page(s): 7405 - 7413
11/01/2007 Authors: Wang X; Yue P; Chan C-B; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun S-Y
Targeting angiogenesis in head and neck cancer.
Curr Cancer Drug Targets Volume: 7 Page(s): 643 - 649
11/01/2007 Authors: Saba NF; Shin DM; Khuri FR
c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.
Cancer Biol Ther Volume: 6 Page(s): 1614 - 1620
10/01/2007 Authors: Zou W; Chen S; Liu X; Yue P; Sporn MB; Khuri FR; Sun S-Y
Erythropoietins in oncology
NEW ENGLAND JOURNAL OF MEDICINE Volume: 357 Page(s): 1262 - 1262
09/20/2007 Authors: Lattanzi SC
Erythropoietins in oncology.
N Engl J Med Volume: 357 Page(s): 1262
09/20/2007 Authors: Lattanzi SC
Can statins pass the aspirin litmus test in cancer?
J Clin Oncol Volume: 25 Page(s): 3395 - 3396
08/10/2007 Authors: Kauh J; Khuri FR
Retinoids and rexinoids in lung cancer biology and therapy
JOURNAL OF THORACIC ONCOLOGY Volume: 2 Page(s): S174 - S174
08/01/2007 Authors: Khuri FR
Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.
Cancer Res Volume: 67 Page(s): 6946 - 6955
07/15/2007 Authors: Song JH; Tse MCL; Bellail A; Phuphanich S; Khuri F; Kneteman NM; Hao C
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Blood Volume: 110 Page(s): 360 - 369
07/01/2007 Authors: Dong S; Kang S; Gu T-L; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
Mol Cancer Ther Volume: 6 Page(s): 2029 - 2038
07/01/2007 Authors: Elrod HA; Lin Y-D; Yue P; Wang X; Lonial S; Khuri FR; Sun S-Y
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
J Biol Chem Volume: 282 Page(s): 18800 - 18809
06/29/2007 Authors: Sun S-Y; Liu X; Zou W; Yue P; Marcus AI; Khuri FR
Concurrent platinum-based chemotherapy with intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): A retrospective single institution analysis
Volume: 25
06/20/2007 Authors: Saba NF; Gaultney J; Edelman S; Tighiouart M; Davis LW; Khuri FR; Chen A; Grist W; Shin DM
Weighing the hazards of erythropoiesis stimulation in patients with cancer.
N Engl J Med Volume: 356 Page(s): 2445 - 2448
06/14/2007 Authors: Khuri FR
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Cancer Res Volume: 67 Page(s): 4981 - 4988
05/15/2007 Authors: Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun S-Y
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Cancer Res Volume: 67 Page(s): 4973 - 4980
05/15/2007 Authors: Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun S-Y
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Cancer Biol Ther Volume: 6 Page(s): 749 - 754
05/01/2007 Authors: Jung CS; Zhou Z; Khuri FR; Sun S-Y
Chemoprevention of squamous cell carcinoma of the head and neck.
Curr Opin Oncol Volume: 19 Page(s): 180 - 187
05/01/2007 Authors: Wrangle JM; Khuri FR
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.
Mol Cancer Ther Volume: 6 Page(s): 1317 - 1328
04/01/2007 Authors: Schafer-Hales K; Iaconelli J; Snyder JP; Prussia A; Nettles JH; El-Naggar A; Khuri FR; Giannakakou P; Marcus AI
Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck.
Head Neck Volume: 29 Page(s): 351 - 361
04/01/2007 Authors: Zhang X; Chen ZG; Khuri FR; Shin DM
State of the art in lung cancer: A glass one-quarter full? The Womiak/Gadgeel article reviewed
ONCOLOGY-NEW YORK Volume: 21 Page(s): 171 - +
02/01/2007 Authors: Khuri FR
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells.
Cancer Biol Ther Volume: 6 Page(s): 99 - 106
01/01/2007 Authors: Zou W; Liu X; Yue P; Khuri FR; Sun S-Y
Moving toward bioadjuvant approaches to head and neck cancer prevention.
Volume: 69 Page(s): S132 - S135
01/01/2007 Authors: Saba NF; Hammond A; Shin DM; Khuri FR
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Cancer Res Volume: 66 Page(s): 11115 - 11119
12/01/2006 Authors: Liu X; Yue P; Schnthal AH; Khuri FR; Sun S-Y
14-3-3 integrates pro-survival signals in hematopoietic cells transformed by diverse leukemogenic tyrosine kinases, and represents a common target.
Volume: 108 Page(s): 337A - 337A
11/16/2006 Authors: Dong S; Kang S; Gu T-L; Kardar S; Lonial S; Khoury HJ; Khuri F; Fu H; Chen J
Farnesyltransferase inhibitors reverse taxane resistance.
Cancer Res Volume: 66 Page(s): 8838 - 8846
09/01/2006 Authors: Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Daz F; Giannakakou P
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
J Clin Oncol Volume: 24 Page(s): 4163 - 4169
09/01/2006 Authors: Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature.
J Clin Pharm Ther Volume: 31 Page(s): 401 - 406
08/01/2006 Authors: Kim KB; Faderl S; Hwang CS; Khuri FR
Targeting protein-protein interactions in signaling pathways for therapeutic interventions
ACTA PHARMACOLOGICA SINICA Volume: 27 Page(s): 26 - 26
07/01/2006 Authors: Du Y; Luhn P; Park H; Sun S; Khuri FR; Fu H
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways.
Semin Cancer Biol Volume: 16 Page(s): 193 - 202
06/01/2006 Authors: Porter GW; Khuri FR; Fu H
Fenretinide activity in retinoid-resistant oral leukoplakia.
Clin Cancer Res Volume: 12 Page(s): 3109 - 3114
05/15/2006 Authors: Lippman SM; Lee JJ; Martin JW; El-Naggar AK; Xu X; Shin DM; Thomas M; Mao L; Fritsche HA; Zhou X
Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me).
Cancer Biol Ther Volume: 5 Page(s): 492 - 497
05/01/2006 Authors: Yue P; Zhou Z; Khuri FR; Sun S-Y
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
J Natl Cancer Inst Volume: 98 Page(s): 441 - 450
04/05/2006 Authors: Khuri FR; Lee JJ; Lippman SM; Kim ES; Cooper JS; Benner SE; Winn R; Pajak TF; Williams B; Shenouda G
Farnesyltransferase inhibitors (FTI) enhance taxol-binding to microtubules and reverse taxane-resistance
Volume: 66
04/01/2006 Authors: O'Brate AM; Marcus AI; Buey R; Zhou J; Thomas SL; Khuri FR; Andreu JM; Diaz F; Giannakakou P
FLIP downregulation and its impact on celecoxib-induced apoptosis in human lung cancer cells
Volume: 66
04/01/2006 Authors: Liu X; Yue P; Khuri FR; Sun S-Y
The future of cancer prevention: ripe for a revolution.
Future Oncol Volume: 2 Page(s): 159 - 160
04/01/2006 Authors: Sharon E; Khuri FR
Establishment of a rapamycin-resistant cell line that retains sensitivity to PI3 kinase inhibitors.
Volume: 66
04/01/2006 Authors: Wang X; Yue P; Khuri FR; Sun S-Y
Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay.
J Biomol Screen Volume: 11 Page(s): 269 - 276
04/01/2006 Authors: Du Y; Masters SC; Khuri FR; Fu H
PPAR gamma ligands induce death receptor 5 (DR5) expression and redistribution in lipid rafts and enhance TRAIL-induced apoptosis in human lung cancer cells
Volume: 66
04/01/2006 Authors: Zou W; Liu X; Yue P; Khuri FR; Sun S-Y
Prognostic significance of DAP kinase promoter hypermethylation in stage I non-small cell lung cancer patients.
Volume: 66
04/01/2006 Authors: Zhou X; Wen S; Tang X; Liu D; Khuri FR; Hardy RJ; Lee ES; Tortolero-Luna G; Shen Y; Mao L
Targeting mTOR signaling for lung cancer therapy.
J Thorac Oncol Volume: 1 Page(s): 109 - 111
02/01/2006 Authors: Sun S-Y; Fu H; Khuri FR
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Oncology (Williston Park) Volume: 20 Page(s): 153 - 161
02/01/2006 Authors: Saba NF; Khuri FR; Shin DM
Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Clin Cancer Res Volume: 12 Page(s): 653 - 661
01/15/2006 Authors: Oh S-H; Kim W-Y; Kim J-H; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Clin Cancer Res Volume: 12 Page(s): 273 - 280
01/01/2006 Authors: Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun S-Y
Taxanes in the treatment of non-small cell lung cancer.
Treat Respir Med Volume: 5 Page(s): 181 - 191
01/01/2006 Authors: Fanucchi M; Khuri FR
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Cancer Res Volume: 66 Page(s): 315 - 323
01/01/2006 Authors: Han S; Khuri FR; Roman J
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Blood Volume: 106 Page(s): 4322 - 4329
12/15/2005 Authors: David E; Sun S-Y; Waller EK; Chen J; Khuri FR; Lonial S
Correlation of cyclooxygenase-2 (COX-2) expression with tumor progression and survival in head and neck cancer (HNC)
Volume: 14 Page(s): 2689S - 2689S
11/01/2005 Authors: Klass C; Choe MS; Tighiouart M; Shin HJ; Rogatko A; Muller S; Papadimitrakopoulou VA; Khuri FR; Hong WK; Chen GZ
A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.
Int J Radiat Oncol Biol Phys Volume: 63 Page(s): 717 - 724
11/01/2005 Authors: Johnson FM; Garden AS; Palmer JL; Shin DM; Morrison W; Papadimitrakopoulou V; Khuri F; Clayman G; Goepfert H; Ang KK
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Cancer Res Volume: 65 Page(s): 9169 - 9175
10/15/2005 Authors: Liu X; Yue P; Khuri FR; Sun S-Y
Chemoprevention strategies for patients with lung cancer in the context of screening.
Clin Lung Cancer Volume: 7 Page(s): 92 - 99
09/01/2005 Authors: Saba NF; Khuri FR
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Clin Cancer Res Volume: 11 Page(s): 6261 - 6269
09/01/2005 Authors: Zhang X; Chen ZG; Choe MS; Lin Y; Sun S-Y; Wieand HS; Shin HJC; Chen A; Khuri FR; Shin DM
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer Res Volume: 65 Page(s): 7052 - 7058
08/15/2005 Authors: Sun S-Y; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Cancer Volume: 104 Page(s): 561 - 569
08/01/2005 Authors: Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KMW; Papadimitrakopoulou V
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Clin Cancer Res Volume: 11 Page(s): 5342 - 5346
08/01/2005 Authors: Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells.
Cancer Res Volume: 65 Page(s): 6354 - 6363
07/15/2005 Authors: Jin F; Liu X; Zhou Z; Yue P; Lotan R; Khuri FR; Chung LWK; Sun S-Y
Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
Cancer Res Volume: 65 Page(s): 5841 - 5847
07/01/2005 Authors: Ren H; Tai S-K; Khuri F; Chu Z; Mao L
A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin (R)), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Volume: 49 Page(s): S31 - S31
07/01/2005 Authors: Gatzemeier U; Blumenschein G; Jotte R; von Pawel J; Miller W; Khuri F; Rigas J; Mabry M; Dziewanowska Z; Negro-Vilar A
Role of cyclooxygenase-2 (COX-2) expression in tumor progression and survival in the squamous cell carcinoma of the head and neck (HNSCC).
Volume: 23 Page(s): 502S - 502S
06/01/2005 Authors: Choe MS; Tighiouart M; Rogatko A; Muller S; Shin HJ; Francisco M; Papadimitrakopoulou VA; Khuri FR; Hong WK; Chen Z
Chemoprevention of lung cancer: concepts and strategies.
Expert Rev Anticancer Ther Volume: 5 Page(s): 549 - 565
06/01/2005 Authors: Cohen V; Khuri FR
GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Volume: 23 Page(s): 504S - 504S
06/01/2005 Authors: Zhang X; Choe MS; Lee JE; Muller S; Tighiouart M; Rogatko A; Glisson BS; Chen Z; Khuri FR; Shin DM
A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC).
Volume: 23 Page(s): 516S - 516S
06/01/2005 Authors: Yang CH; Kies MS; Glisson B; Burke BJ; Ginsberg LE; Truong MT; Sugrue MM; Hong WK; Khuri FR; Kim ES
Role of cyclooxygenase-2 (COX-2) expression in tumor progression and survival in the squamous cell carcinoma of the head and neck (HNSCC).
J Clin Oncol Volume: 23 Page(s): 5508
06/01/2005 Authors: Choe MS; Tighiouart M; Rogatko A; Muller S; Shin HJ; Francisco M; Papadimitrakopoulou VA; Khuri FR; Hong WK; Chen Z
GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
J Clin Oncol Volume: 23 Page(s): 5519
06/01/2005 Authors: Zhang X; Choe MS; Lee JE; Muller S; Tighiouart M; Rogatko A; Glisson BS; Chen Z; Khuri FR; Shin DM
Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Clin Cancer Res Volume: 11 Page(s): 4151 - 4159
06/01/2005 Authors: Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Volume: 23 Page(s): 1094S - 1094S
06/01/2005 Authors: Blumenschein GR; Khuri F; Gatzemeier U; Miller WH; von Pawel J; Rigas JR; Herbst RS; Dziewanowska Z; Negro-Vilar A; Mabry M
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Volume: 23 Page(s): 621S - 621S
06/01/2005 Authors: Blumenschein GR; Khuri F; Gatzemeier U; Miller WH; von Pawel J; Rigas JR; Herbst RS; Dziewanowska Z; Negro-Vilar A; Mabry M
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Cancer Res Volume: 65 Page(s): 3883 - 3893
05/01/2005 Authors: Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao T-P; Khuri FR; Giannakakou P
Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.
Arch Otolaryngol Head Neck Surg Volume: 131 Page(s): 304 - 307
04/01/2005 Authors: Seixas-Silva JA; Richards T; Khuri FR; Wieand HS; Kim E; Murphy B; Francisco M; Hong WK; Shin DM
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
J Natl Cancer Inst Volume: 97 Page(s): 94 - 102
01/19/2005 Authors: Lippman SM; Goodman PJ; Klein EA; Parnes HL; Thompson IM; Kristal AR; Santella RM; Probstfield JL; Moinpour CM; Albanes D
Lung cancer.
Volume: 25 Page(s): 1 - 12
01/01/2005 Authors: Maghfoor I; Perry MC
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Oncology Volume: 68 Page(s): 10 - 17
01/01/2005 Authors: Saba N; Khuri F
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Oncology Volume: 68 Page(s): 18 - 22
01/01/2005 Authors: Saba N; Khuri F
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies.
Cancer Volume: 101 Page(s): 2837 - 2842
12/15/2004 Authors: Do K-A; Johnson MM; Lee JJ; Wu XF; Dong Q; Hong WK; Khuri FR; Spitz MR
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
J Natl Cancer Inst Volume: 96 Page(s): 1769 - 1780
12/01/2004 Authors: Liu X; Yue P; Zhou Z; Khuri FR; Sun S-Y
Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Semin Oncol Volume: 31 Page(s): 809 - 815
12/01/2004 Authors: Fanucchi M; Khuri FR
Combination of farnesyl transferase inhibition (lonafarnib) and proteasome inhibition (bortezomib) results in rapid caspase activation and down regulation of p-AKT in myeloma cell lines and primary myeloma cells.
Volume: 104 Page(s): 678A - 678A
11/16/2004 Authors: David E; Sun SY; Khuri FR; Lonial S
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
Volume: 22 Page(s): 4575 - 4583
11/15/2004 Authors: Lu C; Soria J-C; Tang X; Xu X-C; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L
The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Cancer Biol Ther Volume: 3 Page(s): 1092 - 1098
11/01/2004 Authors: Sun S-Y; Zhou Z; Wang R; Fu H; Khuri FR
Induction chemotherapy for resectable non-small-cell lung cancer - The Patel/Blum/Argiris article reviewed
ONCOLOGY-NEW YORK Volume: 18 Page(s): 1606 - +
11/01/2004 Authors: Saba NF; Khuri FR
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
J Clin Oncol Volume: 22 Page(s): 4384 - 4393
11/01/2004 Authors: Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
J Natl Cancer Inst Volume: 96 Page(s): 1536 - 1548
10/20/2004 Authors: Lee H-Y; Moon H; Chun K-H; Chang Y-S; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Cancer Res Volume: 64 Page(s): 7570 - 7578
10/15/2004 Authors: Zou W; Liu X; Yue P; Zhou Z; Sporn MB; Lotan R; Khuri FR; Sun S-Y
Retinoids in lung cancer: friend, foe, or fellow traveler?
J Clin Oncol Volume: 22 Page(s): 3435 - 3437
09/01/2004 Authors: Khuri FR; Lotan R
Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer.
Oncogene Volume: 23 Page(s): 6569 - 6580
08/26/2004 Authors: Chang YS; Wang L; Suh Y-A; Mao L; Karpen SJ; Khuri FR; Hong WK; Lee H-Y
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
Clin Cancer Res Volume: 10 Page(s): 5299 - 5312
08/15/2004 Authors: Chu RL; Post DE; Khuri FR; Van Meir EG
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
J Clin Oncol Volume: 22 Page(s): 3230 - 3237
08/15/2004 Authors: Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Ann Oncol Volume: 15 Page(s): 1187 - 1193
08/01/2004 Authors: Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X
p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Cancer Res Volume: 64 Page(s): 5078 - 5083
08/01/2004 Authors: Liu X; Yue P; Khuri FR; Sun S-Y
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial.
Volume: 22 Page(s): 491S - 491S
07/15/2004 Authors: Kim ES; Lee J; Feng L; Lippman S; Shenouda G; Hodson I; Vokes E; Khuri F; Hong WK; Anderson MD
Definitive treatment of intermediate stage laryngeal squamous cell (SCC/L) cancer with chemotherapy (CT).
Volume: 22 Page(s): 496S - 496S
07/15/2004 Authors: Kies MS; Lewin JS; Diaz EM; Gillenwater AM; Glisson BS; Ginsberg LE; Clayman GL; Taylor S; Gillaspy KA; Khuri FR
Chemoprevention of lung cancer.
Curr Opin Pulm Med Volume: 10 Page(s): 279 - 283
07/01/2004 Authors: Cohen V; Khuri FR
Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.
J Biol Chem Volume: 279 Page(s): 26287 - 26299
06/18/2004 Authors: Takada Y; Khuri FR; Aggarwal BB
Novel agents in the treatment of lung cancer: conference summary statement.
Clin Cancer Res Volume: 10 Page(s): 4199s - 4204s
06/15/2004 Authors: Lynch TJ; Adjei AA; Bunn PA; DuBois RN; Gandara DR; Giaccone G; Govindan R; Herbst RS; Johnson BE; Khuri FR
Molecularly targeted approaches to the chemoprevention of lung cancer.
Volume: 10 Page(s): 4249s - 4253s
06/15/2004 Authors: Khuri FR; Cohen V
Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
Endocr Relat Cancer Volume: 11 Page(s): 191 - 205
06/01/2004 Authors: O'Regan RM; Khuri FR
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
Lung Cancer Volume: 44 Page(s): 369 - 379
06/01/2004 Authors: Kim ES; Putnam JB; Komaki R; Walsh GL; Ro JY; Shin HJ; Truong M; Moon H; Swisher SG; Fossella FV
Novel targeted agents in the treatment of lung cancer.
Expert Opin Investig Drugs Volume: 13 Page(s): 609 - 629
06/01/2004 Authors: Saba N; Khuri F
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clin Cancer Res Volume: 10 Page(s): 2968 - 2976
05/01/2004 Authors: Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y
A qualitative study of head and neck cancer.
Support Care Cancer Volume: 12 Page(s): 338 - 346
05/01/2004 Authors: Moore RJ; Chamberlain RM; Khuri FR
Emerging drugs for head and neck cancer.
Expert Opin Emerg Drugs Volume: 9 Page(s): 91 - 104
05/01/2004 Authors: Rhee JC; Khuri FR; Shin DM
The care of the lung cancer patient in the 21st century: A new age
Volume: 31 Page(s): 11 - 15
04/01/2004 Authors: Smith W; Khuri FR
Novel agents and incremental advances in the treatment of head and neck cancer.
Semin Oncol Volume: 31 Page(s): 3 - 10
04/01/2004 Authors: Khuri FR; Jain SR
The care of the lung cancer patient in the 21st century: a new age.
Semin Oncol Volume: 31 Page(s): 11 - 15
04/01/2004 Authors: Smith W; Khuri FR
A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.
Cancer Volume: 100 Page(s): 991 - 998
03/01/2004 Authors: Johnson FM; Garden A; Palmer JL; Kies M; Clayman G; Brumfield B; Khuri FR; Morrison W; Papadimitrakopoulou V; Diaz EM
Communicating suffering in primary stage head and neck cancer.
Eur J Cancer Care (Engl) Volume: 13 Page(s): 53 - 64
03/01/2004 Authors: Moore RJ; Chamberlain RM; Khuri FR
Chemoprevention in lung cancer.
Curr Probl Cancer Volume: 28 Page(s): 287 - 306
01/01/2004 Authors: Saba N; Jain S; Khuri F
Sex differences in survival in non-small cell lung cancer patients 1974-1998.
Acta Oncol Volume: 43 Page(s): 57 - 64
01/01/2004 Authors: Moore R; Doherty D; Chamberlain R; Khuri F
Prevention of head and neck cancer: current status and future prospects.
Curr Probl Cancer Volume: 28 Page(s): 265 - 286
01/01/2004 Authors: Jain S; Khuri FR; Shin DM
Advances in chemoprevention of head and neck cancer.
Oncologist Volume: 9 Page(s): 302 - 311
01/01/2004 Authors: Rhee JC; Khuri FR; Shin DM
Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review.
Oncology Volume: 66 Page(s): 79 - 93
01/01/2004 Authors: Moore RJ; Chamberlain RM; Khuri FR
Targeting 14-3-3/ligand interactions in NSCLC.
Volume: 9 Page(s): 6242S - 6242S
12/01/2003 Authors: Park HR; Luhn PA; Zhang HY; Montoya LM; Sun SY; Khuri FR; Fu H
The farnesyltransferase inhibitor lonafarnib induces growth inhibition and apoptosis in human lung cancer cells without downregulating
Volume: 9 Page(s): 6095S - 6095S
12/01/2003 Authors: Sun SY; Zhou ZM; Wang RX; Khuri FR
Molecularly targeted approaches to the chemoprevention of lung cancer
Volume: 12 Page(s): 1357S - 1357S
11/01/2003 Authors: Khuri F
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Cancer Treat Rev Volume: 29 Page(s): 407 - 415
10/01/2003 Authors: Herbst RS; Khuri FR
Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.
South Med J Volume: 96 Page(s): 1031 - 1033
10/01/2003 Authors: Richards S; Umbreit JN; Fanucchi MP; Giblin J; Khuri F
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Clin Lung Cancer Volume: 5 Suppl 1 Page(s): S36 - S40
09/01/2003 Authors: Khuri FR
Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Cancer Res Volume: 63 Page(s): 4796 - 4800
08/15/2003 Authors: Chun K-H; Lee H-Y; Hassan K; Khuri F; Hong WK; Lotan R
Replicative oncolytic adenoviruses in multimodal cancer regimens.
Hum Gene Ther Volume: 14 Page(s): 933 - 946
07/01/2003 Authors: Post DE; Khuri FR; Simons JW; Van Meir EG
Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.
Clin Cancer Res Volume: 9 Page(s): 1785 - 1791
05/01/2003 Authors: Soria J-C; Moon C; Kemp BL; Liu DD; Feng L; Tang X; Chang Y-S; Mao L; Khuri FR
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
J Clin Oncol Volume: 21 Page(s): 1167 - 1173
03/15/2003 Authors: Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma (vol 95, pg 340, 2002)
CANCER Volume: 97 Page(s): 1367 - 1367
03/01/2003 Authors: Herbst RS; Khuri FR; Lu C
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States).
Cancer Causes Control Volume: 14 Page(s): 131 - 138
03/01/2003 Authors: Do K-A; Johnson MM; Doherty DA; Lee JJ; Wu XF; Dong Q; Hong WK; Khuri FR; Fu KK; Spitz MR
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial.
J Natl Cancer Inst Volume: 95 Page(s): 206 - 214
02/05/2003 Authors: Kurie JM; Lotan R; Lee JJ; Lee JS; Morice RC; Liu DD; Xu X-C; Khuri FR; Ro JY; Hittelman WN
Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers.
J Natl Cancer Inst Volume: 95 Page(s): 165 - 168
01/15/2003 Authors: Soria J-C; Xu X; Liu DD; Lee JJ; Kurie J; Morice RC; Khuri F; Mao L; Hong WK; Lotan R
Progress in lung cancer chemoprevention.
Cancer Control Volume: 10 Page(s): 315 - 324
01/01/2003 Authors: Cohen V; Khuri FR
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Clin Cancer Res Volume: 9 Page(s): 93 - 101
01/01/2003 Authors: Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K
Treatment of non-small-cell lung cancer in older persons - The Basche/Kelly article reviewed
ONCOLOGY-NEW YORK Volume: 17 Page(s): 43 - +
01/01/2003 Authors: Cohen V; Khuri FR
Chemoprevention in lung cancer.
J Med Assoc Ga Volume: 92 Page(s): 27 - 33
01/01/2003 Authors: Reddy SC; Khuri FR
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Clin Cancer Res Volume: 8 Page(s): 3796 - 3802
12/01/2002 Authors: Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee H-Y
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Clin Cancer Res Volume: 8 Page(s): 3669 - 3675
12/01/2002 Authors: Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee H-Y
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
J Clin Oncol Volume: 20 Page(s): 4440 - 4447
11/15/2002 Authors: Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA
Molecularly therapeutic approaches to lung cancer chemoprevention.
Volume: 11 Page(s): 1244S - 1244S
10/01/2002 Authors: Khuri FR; Kim ES; Hong WK
hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Clin Cancer Res Volume: 8 Page(s): 2883 - 2889
09/01/2002 Authors: Wang L; Soria J-C; Kemp BL; Liu DD; Mao L; Khuri FR
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Volume: 95 Page(s): 340 - 353
07/15/2002 Authors: Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KMW; Shin DM; Papadimitrakopoulou VA; Kurie JM
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Cancer Volume: 95 Page(s): 322 - 330
07/15/2002 Authors: Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A
Farnesyltransferase inhibitors: a promising future in cancer treatment.
Clin Lung Cancer Volume: 4 Page(s): 63 - 64
07/01/2002 Authors: Khuri FR; Cohen V
Chemoprevention of lung cancer.
Curr Oncol Rep Volume: 4 Page(s): 341 - 346
07/01/2002 Authors: Kim ES; Khuri FR
Diffuse malignant mesothelioma of the pleural space and its management - The Zellos/Sugarbaker Article Reviewed
ONCOLOGY-NEW YORK Volume: 16 Page(s): 917 - +
07/01/2002 Authors: Khuri FR; Smythe WR
Docetaxel and radiation as combined-modality therapy.
Oncology (Williston Park) Volume: 16 Page(s): 97 - 105
06/01/2002 Authors: Kim ES; Khuri FR
Docetaxel for locally advanced or metastatic non-small-cell lung cancer current data and future directions as front-line therapy
ONCOLOGY-NEW YORK Volume: 16 Page(s): 53 - 62
06/01/2002 Authors: Khuri FR
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Oncology (Williston Park) Volume: 16 Page(s): 53 - 62
06/01/2002 Authors: Khuri FR
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Clin Cancer Res Volume: 8 Page(s): 1178 - 1184
05/01/2002 Authors: Soria J-C; Lee H-Y; Lee JI; Wang L; Issa J-P; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.
Radiother Oncol Volume: 63 Page(s): 187 - 193
05/01/2002 Authors: Grgoire V; Ang KK; Rosier J-F; Beauduin M; Garden AS; Hamoir M; Hittelman WN; Humblet Y; Khuri FR; Milas L
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
J Clin Oncol Volume: 20 Page(s): 1593 - 1599
03/15/2002 Authors: Glisson BS; Murphy BA; Frenette G; Khuri FR; Forastiere AA
Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.
Semin Oncol Volume: 29 Page(s): 15 - 26
02/01/2002 Authors: Arteaga CL; Khuri F; Krystal G; Sebti S
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
J Clin Oncol Volume: 20 Page(s): 364 - 370
01/15/2002 Authors: Shin DM; Glisson BS; Khuri FR; Clifford JL; Clayman G; Benner SE; Forastiere AA; Ginsberg L; Liu D; Lee JJ
Chemoprevention of aerodigestive tract cancers.
Volume: 53 Page(s): 223 - 243
01/01/2002 Authors: Kim ES; Hong WK; Khuri FR
New targets for the treatment of advanced non-small cell lung cancer.
Cancer Chemother Biol Response Modif Volume: 20 Page(s): 717 - 761
01/01/2002 Authors: Massarelli E; Onn A; Zinner R; Khuri FR; Kim ES; Herbst RS
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Volume: 12 Page(s): 46 - 49
01/01/2002 Authors: Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V
Chemoprevention of lung cancer: current status and future prospects.
Cancer Metastasis Rev Volume: 21 Page(s): 349 - 362
01/01/2002 Authors: Cohen V; Khuri FR
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
Lung Cancer Volume: 34 Page(s): 427 - 432
12/01/2001 Authors: Kim ES; Lu C; Khuri FR; Tonda M; Glisson BS; Liu D; Jung M; Hong WK; Herbst RS
Epidermal growth factor receptor biology (IMC-C225).
Curr Opin Oncol Volume: 13 Page(s): 506 - 513
11/01/2001 Authors: Kim ES; Khuri FR; Herbst RS
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Volume: 92 Page(s): 2364 - 2373
11/01/2001 Authors: Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang X
A phase I study of continuous infusion of TNP-470 alone or in combination with paclitaxel and carboplatin in adult patients with solid tumors.
CLINICAL CANCER RESEARCH Volume: 7 Page(s): 3659S - 3659S
11/01/2001 Authors: Blumenschein GR; Fossella FV; Pisters KM; Shin DM; Khuri FR; Lu C; Kies MS; Glisson BS; Zinner RG; Schaerer R
ZD1839 (Iressa) in non-small-cell lung cancer.
Clin Lung Cancer Volume: 3 Page(s): 27 - 32
08/01/2001 Authors: Herbst RS; Khuri FR; Fossella FV; Glisson BS; Kies MS; Pisters KM; Riddle JR; Terry KA; Lee JS
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
Cancer Epidemiol Biomarkers Prev Volume: 10 Page(s): 823 - 829
08/01/2001 Authors: Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM
Long-term impact of smoking on lung epithelial proliferation in current and former smokers.
J Natl Cancer Inst Volume: 93 Page(s): 1081 - 1088
07/18/2001 Authors: Lee JJ; Liu D; Lee JS; Kurie JM; Khuri FR; Ibarguen H; Morice RC; Walsh G; Ro JY; Broxson A
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
J Clin Oncol Volume: 19 Page(s): 3010 - 3017
06/15/2001 Authors: Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V
Recent advances in the management of squamous cell carcinoma of the head and neck.
Expert Rev Anticancer Ther Volume: 1 Page(s): 99 - 110
06/01/2001 Authors: Kim KB; Khuri FR; Shin DM
Emerging therapies in non-small-cell lung cancer.
Ann Oncol Volume: 12 Page(s): 739 - 744
06/01/2001 Authors: Khuri FR; Herbst RS; Fossella FV
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
J Clin Oncol Volume: 19 Page(s): 2626 - 2637
05/15/2001 Authors: Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Clin Cancer Res Volume: 7 Page(s): 1204 - 1213
05/01/2001 Authors: Shin DM; Donato NJ; Perez-Soler R; Shin HJ; Wu JY; Zhang P; Lawhorn K; Khuri FR; Glisson BS; Myers J
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
J Natl Cancer Inst Volume: 93 Page(s): 605 - 618
04/18/2001 Authors: Lippman SM; Lee JJ; Karp DD; Vokes EE; Benner SE; Goodman GE; Khuri FR; Marks R; Winn RJ; Fry W
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Clin Cancer Res Volume: 7 Page(s): 861 - 867
04/01/2001 Authors: Khuri FR; Wu H; Lee JJ; Kemp BL; Lotan R; Lippman SM; Feng L; Hong WK; Xu XC
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers.
Cancer Epidemiol Biomarkers Prev Volume: 10 Page(s): 311 - 318
04/01/2001 Authors: Khuri FR; Lee JS; Lippman SM; Lee JJ; Kalapurakal S; Yu R; Ro JY; Morice RC; Hong WK; Hittelman WN
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Volume: 91 Page(s): 1316 - 1323
04/01/2001 Authors: Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Phase I trial of oral green tea extract in adult patients with solid tumors.
J Clin Oncol Volume: 19 Page(s): 1830 - 1838
03/15/2001 Authors: Pisters KM; Newman RA; Coldman B; Shin DM; Khuri FR; Hong WK; Glisson BS; Lee JS
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
J Clin Oncol Volume: 19 Page(s): 289 - 298
01/15/2001 Authors: Nemunaitis J; Khuri F; Ganly I; Arseneau J; Posner M; Vokes E; Kuhn J; McCarty T; Landers S; Blackburn A
Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee.
Int J Radiat Oncol Biol Phys Volume: 51 Page(s): 39 - 43
01/01/2001 Authors: Ang K; Weber R; Vokes E; Trotti A; Chapman D; Cooper J; Forastiere A; Fu KK; Hammond E; Khuri F
Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx.
Ethn Health Volume: 6 Page(s): 165 - 177
01/01/2001 Authors: Moore RJ; Doherty DA; Do KA; Chamberlain RM; Khuri FR
A voice that wraps around the body--communication problems in the advanced stages of non-small cell lung cancer.
Yale J Biol Med Volume: 74 Page(s): 367 - 382
01/01/2001 Authors: Moore RJ; Chamberlain RM; Khuri FR
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Cancer Res Volume: 60 Page(s): 6359 - 6366
11/15/2000 Authors: Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B
Phase I study of farnesyl transferase inhibitors (FTI) SCH6336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety.
Volume: 6 Page(s): 4547S - 4547S
11/01/2000 Authors: Khuri FR; Glisson BS; Meyers ML; Statkevich P; Hong WK
Phase I/II trial of bexarotene (Targretin (R)) with chemotherapy for chemo-naive patients with advanced non-small cell lung cancer.
Volume: 6 Page(s): 4487S - 4488S
11/01/2000 Authors: Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Reich SD; Hong WK
Prevention of lung cancer. The new millennium.
Chest Surg Clin N Am Volume: 10 Page(s): 663 - v
11/01/2000 Authors: Kim ES; Hong WK; Khuri FR
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
J Natl Cancer Inst Volume: 92 Page(s): 1511 - 1516
09/20/2000 Authors: Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer.
J Clin Oncol Volume: 18 Page(s): 2798 - 2804
08/01/2000 Authors: Khuri FR; Lotan R; Kemp BL; Lippman SM; Wu H; Feng L; Lee JJ; Cooksley CS; Parr B; Chang E
N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Clin Cancer Res Volume: 6 Page(s): 2973 - 2979
08/01/2000 Authors: Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.
Cancer Res Volume: 60 Page(s): 4000 - 4004
08/01/2000 Authors: Soria JC; Jang SJ; Khuri FR; Hassan K; Liu D; Hong WK; Mao L
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Nat Med Volume: 6 Page(s): 879 - 885
08/01/2000 Authors: Khuri FR; Nemunaitis J; Ganly I; Arseneau J; Tannock IF; Romel L; Gore M; Ironside J; MacDougall RH; Heise C
Antisense approaches enter the clinic.
Clin Cancer Res Volume: 6 Page(s): 1607 - 1610
05/01/2000 Authors: Khuri FR; Kurie JM
Adenocarcinoma of the lung in young patients: the M. D. Anderson experience.
Cancer Volume: 88 Page(s): 1837 - 1841
04/15/2000 Authors: Liu NS; Spitz MR; Kemp BL; Cooksley C; Fossella FV; Lee JS; Hong WK; Khuri FR
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
Cancer Gene Ther Volume: 7 Page(s): 530 - 536
04/01/2000 Authors: Yen N; Ioannides CG; Xu K; Swisher SG; Lawrence DD; Kemp BL; El-Naggar AK; Cristiano RJ; Fang B; Glisson BS
Lung cancer chemoprevention.
Semin Surg Oncol Volume: 18 Page(s): 100 - 105
03/01/2000 Authors: Khuri FR; Lippman SM
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Clin Cancer Res Volume: 6 Page(s): 790 - 797
03/01/2000 Authors: Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK
Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer.
Clin Cancer Res Volume: 6 Page(s): 559 - 565
02/01/2000 Authors: Zhou X; Kemp BL; Khuri FR; Liu D; Lee JJ; Wu W; Hong WK; Mao L
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
J Clin Oncol Volume: 18 Page(s): 609 - 622
02/01/2000 Authors: Nemunaitis J; Swisher SG; Timmons T; Connors D; Mack M; Doerksen L; Weill D; Wait J; Lawrence DD; Kemp BL
Paclitaxel and ifosfamide-based chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck
SEMINARS IN ONCOLOGY Volume: 26 Page(s): 59 - 59
12/01/1999 Authors: Shin DM; Khuri FR; Glisson BS; Papadimitrakopoulou V; Ginsberg L; Lippman SM; Hong WK
Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Cancer Res Volume: 59 Page(s): 4798 - 4803
10/01/1999 Authors: Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
J Clin Oncol Volume: 17 Page(s): 2390 - 2395
08/01/1999 Authors: Garden AS; Glisson BS; Ang KK; Morrison WH; Lippman SM; Byers RM; Geara F; Clayman GL; Shin DM; Callender DL
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
J Natl Cancer Inst Volume: 91 Page(s): 763 - 771
05/05/1999 Authors: Swisher SG; Roth JA; Nemunaitis J; Lawrence DD; Kemp BL; Carrasco CH; Connors DG; El-Naggar AK; Fossella F; Glisson BS
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: Preliminary results of two pilot trials using paclitaxel and cisplatin
SEMINARS IN RADIATION ONCOLOGY Volume: 9 Page(s): 64 - 69
04/01/1999 Authors: Flood W; Lee DJ; Trotti A; Spencer S; Murphy B; Khuri F; DeConti R; Wheeler R; Forastiere AA
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.
Semin Radiat Oncol Volume: 9 Page(s): 64 - 69
04/01/1999 Authors: Flood W; Lee DJ; Trotti A; Spencer S; Murphy B; Khuri F; DeConti R; Wheeler R; Forastiere AA
Paclitaxel, ifosfamide, and carboplatin (TIC) in patients with recurrent or metastatic head and neck cancer: Preliminary results
SEMINARS IN ONCOLOGY Volume: 26 Page(s): 135 - 135
02/01/1999 Authors: Shin DM; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Glisson BS; Hong WK
Phase II trials of intratumoral ONYX-015, an E1B 55-kDa gene-deleted adenovirus, alone and in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Volume: 5 Page(s): S26 - S26
11/01/1998 Authors: Nemunaitis J; Khuri F; Ganly I; Tannock I; Kuhn J; McCartey T; Heise C; Posner M; Kaye S; Romel L
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers.
J Natl Cancer Inst Volume: 90 Page(s): 991 - 995
07/01/1998 Authors: Kurie JM; Lee JS; Morice RC; Walsh GL; Khuri FR; Broxson A; Ro JY; Franklin WA; Yu R; Hong WK
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Semin Oncol Volume: 25 Page(s): 40 - 44
04/01/1998 Authors: Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
J Clin Oncol Volume: 16 Page(s): 1325 - 1330
04/01/1998 Authors: Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
SEMINARS IN ONCOLOGY Volume: 25 Page(s): 40 - 44
04/01/1998 Authors: Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.
J Interferon Cytokine Res Volume: 18 Page(s): 241 - 245
04/01/1998 Authors: Khuri FR; Fossella FV; Lee JS; Murphy WK; Shin DM; Markowitz AB; Glisson BS
Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract.
J Natl Cancer Inst Volume: 90 Page(s): 243 - 245
02/04/1998 Authors: Spitz MR; Lippman SM; Jiang H; Lee JJ; Khuri F; Hsu TC; Trizna Z; Schantz SP; Benner S; Hong WK
The role of paclitaxel/carboplatin chemotherapy as a primary treatment of brain metastases in non-small cell lung cancer
Volume: 9 Page(s): 172 - 172
01/01/1998 Authors: Lee JS; Pisters KMW; Komaki R; Glisson BS; Perez-Soler R; Khuri FR; Delclos ME; Fossella FV
Chemoprevention of lung cancer
Page(s): 263 - 272
01/01/1998 Authors: Pastorino U
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Semin Oncol Volume: 24 Page(s): S19-33-S19-37
12/01/1997 Authors: Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Recent advances in pacilitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck
Volume: 24 Page(s): S33 - S37
12/01/1997 Authors: Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer.
Cancer Epidemiol Biomarkers Prev Volume: 6 Page(s): 687 - 692
09/01/1997 Authors: Spitz MR; McPherson RS; Jiang H; Hsu TC; Trizna Z; Lee JJ; Lippman SM; Khuri FR; Steffen-Batey L; Chamberlain RM
Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report.
Semin Oncol Volume: 24 Page(s): S12-52-S12-55
08/01/1997 Authors: Lee JS; Pisters KM; Komaki R; Glisson BS; Khuri FR; Schea R; Fossella FV
Clonal genetic alterations in the lungs of current and former smokers.
J Natl Cancer Inst Volume: 89 Page(s): 857 - 862
06/18/1997 Authors: Mao L; Lee JS; Kurie JM; Fan YH; Lippman SM; Lee JJ; Ro JY; Broxson A; Yu R; Morice RC
Chemoprevention of respiratory tract cancer.
Hematol Oncol Clin North Am Volume: 11 Page(s): 387 - 408
06/01/1997 Authors: Khuri FR; Kurie JM; Hong WK
Molecular epidemiology and retinoid chemoprevention of head and neck cancer.
J Natl Cancer Inst Volume: 89 Page(s): 199 - 211
02/05/1997 Authors: Khuri FR; Lippman SM; Spitz MR; Lotan R; Hong WK
Advances in the biological study, prevention, and therapy of head and neck cancer
Volume: 8 Page(s): 59 - 70
01/01/1997 Authors: Bernicker EH; Khuri FR; Lippman SM; Hong WK
Retinoic acid-induced transition from protein kinase C beta to protein kinase C alpha in differentiated F9 cells: correlation with altered regulation of proto-oncogene expression by phorbol esters.
Cell Growth Differ Volume: 7 Page(s): 595 - 602
05/01/1996 Authors: Khuri FR; Cho Y; Talmage DA
Waldenstrm's macroglobulinemia with an IgM paraprotein that is both a cold agglutinin and a cryoglobulin and has a suppressive effect on progenitor cell growth.
Transfusion Volume: 34 Page(s): 910 - 914
10/01/1994 Authors: Zago-Novaretti M; Khuri F; Miller KB; Berkman EM
AN IGM-KAPPA PARAPROTEIN IN A PATIENT WITH WALDENSTROM MACROGLOBULIN HAS ANTI-PR COLD ANTIBODY SPECIFICITY AND IS ALSO A CRYOGLOBULIN AND HAS PROGENITOR-CELL SUPPRESSIVE PROPERTIES
Volume: 33 Page(s): S25 - S25
09/01/1993 Authors: NOVARETTI M; KHURI F; MILLER K; BERKMAN E